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Abstract 
Pregnancy is commonly considered a semi-allograft as half of the fetal genome 
derives from the father. However in normal pregnancy several tolerance mechanisms 
have been demonstrated to counteract the maternal immune response. Among these, 
the expression of HLA-G by invasive cytotrophoblasts has shown to play a 
fundamental role in creating a tolerogenic condition at the feto-maternal interface. 
The possible role of soluble HLA-G molecules as a marker for oocyte/embryo 
selection is reviewed comparing the contrasting results present in the literature and 
the significance of HLA-G modulation in assisted reproduction. 
 
 
Key words: assisted reproduction, HLA-G, embryo, oocyte, marker 
 
 
 
1. Actual problems of ART 
The present efficiency of assisted reproduction (ART) seems to be far from desired. 
Until now the probability of a successful pregnancy following an in vitro fertilization 
procedure (IVF) is approximately 18%, with a baby rate of at about 14%. Since the 
birth of the first baby created by ART, Louise Brown in England in 1978 [1], it has 
produced more than 40,000 ART babies each year. However the average success rate 
is still low because of the inability to assess embryo quality using the currently 
available biochemical, genetic and imaging methods. At the present time it is not 
possible to determine for sure the best oocyte to fertilize or the most appropriate 
embryo to transfer. Therefore the usual practice is to transfer two or three embryos to 
improve the chance of a positive pregnancy outcome. Women undergoing ART have 
a 20-fold increased risk of twins and a 400-fold increased risk of triplets or higher 
order pregnancies with a perinatal mortality and morbidity [2,3]. Several studies are 
involved in the identification of non-invasive methods to determine the 
oocyte/embryo quality to allow fewer embryos to be transferred while maintaining or 
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improving pregnancy rates. Since the beginning of this new century the value of non 
classical HLA (Human leukocyte antigen) class I – G antigen as a marker of 
oocyte/embryo competency is under debate. 
 
 
2. Human Major Histocompatibility Complex 
The human Major Histocompatibility Complex (MHC) is a set of molecules encoded 
by a series of genes (~130) located on the short arm of chromosome 6 that are 
responsible for lymphocyte recognition, "antigen presentation" and immune response 
regulation. This gene complex comprises several distinct loci, grouped closely 
together on a 4-6 Mb chromosomal segment. In humans they are called HLA for 
Human Leucocyte Antigens. These antigens can be subdivided into three major 
classes: class I, class II and class III (Figure 1). The class I and class II antigens are 
expressed on cells and tissues whereas class III antigens are mainly serum and body 
fluid proteins (e.g.C4, C2, factor B, TNF, complement components). The class I gene 
complex contains three major loci A, B and C. Each of these loci encodes for an 
alpha-chain polypeptide that associates to ß2-microglobulin, encoded by a gene on 
chromosome 15. The class II gene complex contains at least three loci, DP, DQ and 
DR; each of these loci encodes for one alpha- and one beta-chain polypeptide which 
associate together to form the class II antigens. Since the end of the 80’s a new group 
of antigens has become interesting: the non classical HLA class I molecules [4,5].  
 
 
 
Figure 1. Schematic representation of the HLA region on chromosome 6. The 
non classical HLA class I gene are represented in grey. 
DP DQ DR B C E A G F 
Class II Class III Class I 
HLA 
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3. The non classical HLA class Ib genes 
Non-classical MHC class Ib molecules are closely homologous to classical class Ia 
molecules but are distinguished by their limited polymorphism and low cell surface 
expression. The class Ib molecules are not just vestigial evolutionary remnants of 
classical class Ia molecules; rather some are involved in highly specialized roles, as 
testified by their conservation between different species. The duo comprised of 
HLA-E in human, Qa-1 in mouse and HLA-G in human, Qa-2 in mouse constitutes a 
clear homology between species. In 1993, Warner et al. [6] demonstrated a 
reproductive advantage in mice encoding Qa-2 molecules by preimplantation embryo 
development (Ped) gene, the homologue of human HLA-G gene. The Qa-2 antigen 
has been detected on murine oocytes and early-cleavage and blastocyst-stage 
embryos where it seems to function as a mediator of mitogenic signals between 
embryo and uterine environment [7]. For these characteristics, Qa-2 and HLA-G 
antigens seem to share not only structural but also functional similarities in the 
regulation of immune response, through interaction with both inhibitory and 
activatory receptors [8,9].   
 
 
4. The HLA-G antigen 
HLA-G antigen is a non-classical HLA class I molecule characterized by (i) a low 
allelic polymorphism, (ii) a restricted tissue distribution to trophoblasts and a subset 
of thymic epithelial cells, (iii) mRNA alternative splicing that generates seven 
proteic isoforms and (iv) a tolerogenic and anti-inflammatory biological function 
[10]. 
 
4.1. The HLA-G gene 
The HLA-G gene features low allelic polymorphisms with 36 HLA-G alleles 
acknowledged in the coding region (http//:www.anthonynolan.org.uk/HIG/). HLA-G 
gene is also polymorphic at the 5’-upstream regulatory region (5’ URR) and at the 
3’-untranslated region (3’ UTR) which may contribute to the regulation of HLA-G 
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expression [11]. A 14 bp insertion/deletion polymorphism (rs16375) in exon 8 in the 
3’ UTR has been reported and associated with mRNA stability and HLA-G protein 
expression [12,13] (Figure 2). The allele with an insertion of 14 bp has been 
associated with lower levels of HLA-G expression than the allele with the 14 bp 
deleted [13-15]. An additional alternatively spliced HLA-G transcripts lacking 92 bp 
of the first part of exon 8 is observed within the insertion of 14 bp allele and is 
characterized by a more stable transcript [16].  
Transactivation of classical MHC class I genes is mediated by two groups of 
juxtaposed cis -acting regulatory modules: (i) the up-stream enhancer A and ISRE 
(interferon-sensitive response element) which mediate the constitutive and cytokine-
induced expression; (ii) the S-X-Y module which controls the constitutive and CIITA 
(class II transactivator) mediated transactivation. These modules are divergent in 
HLA-G gene that is unresponsive to NF-kappaB (nuclear factor-kappaB), IRF-1 
(interferon regulatory factor 1), and CIITA mediated induction pathways [17]. The 
HLA-G gene promoter shows a putative interferon-regulatory factor (IRF)-1 binding 
site 746 base pairs upstream from ATG, which is distinct from the interferon-
responsive element within proximal class Ia gene promoters. This control region is 
the putative element which mediates interferon beta-induced expression of the HLA-
G gene [18]. The HLA-G promoter contains three cAMP/PMA response elements 
(CRE/TRE) with binding affinity for REB (rice endosperm bZIP)/ATF (activating 
transcription factor-2) and Fos/Jun proteins. It has been shown that HLA-G 
transactivation is regulated by CREB (cAMP-response element-binding protein), 
CREB-binding protein (CBP), and p300. These features represent the unique 
regulation of HLA-G transcription among the MHC class I genes [19]. 
Epigenetic mechanisms seem to play an important role in HLA-G expression [20,21]. 
The potential role of DNA methylation on HLA-G expression has been tested in 
human tumours considering the effect of the methylation inhibitor 5-aza-
deoxycytidine on the CpG-enriched regulatory region of the HLA-G gene. The 5-aza-
dC treatment results in hypomethylation of putative control sequences within the 5' 
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regulatory region of HLA-G and these changes in methylation correlate with a 
significant increase in expression.  
The HLA-G gene seems not to undergo genomic imprinting, in fact it is co-
dominantly expressed on trophoblast cells [22].  
A post-transcriptional regulation for HLA-G molecules is also possible because of 
the expression in advance of the molecules that are essential for cell surface 
expression of class I molecules, ß2-microglobulin (ß2m) and the transporter for 
antigen processing proteins (TAP1 and TAP2), allowing a rapid accumulation of 
HLA-G protein in differentiating extravillous cytotrophoblast cells [23]. 
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Figure 2. Multiple HLA-G proteins derived from alternative splicing of HLA-G 
mRNA. 
Upper: The HLA-G gene is composed of 8 exons. The α, intracellular and 
transmembrane domains  and the 14 bp insertion/deletion polymorphism (rs16375) in 
exon 8 in the 3’ untranslated region (UTR) are represented. The gene is alternatively 
spliced to yield 7 transcripts. In two of these, a stop sequence in intron 4 results in 
soluble isoforms. 
Lower: The 7 HLA-G proteic isoforms: four membrane-bound (HLA-G1, -G2, -G3, -
G4) and three soluble (HLA-G5, -G6, -G7) molecules. 
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4.2. HLA-G expression and function 
In physiological conditions HLA-G protein presence is restricted to trophoblasts, 
thymus, cornea, nail matrix, pancreas, erythroid and endothelial precursors [24]. 
Unlike HLA class Ia antigens, seven HLA-G isoforms are generated by alternative 
splicing of its primary transcript. Four of them, HLAG1,-G2, -G3 and -G4, are 
membrane-bound, while three, HLA-G5, -G6 and -G7, are soluble molecules 
(Figure 2). The soluble isoforms retain the intron 4 which includes a stop codon and 
leads to the termination of the mRNA translation before the transmembrane domain. 
The HLA-G1 and HLA-G5 structures are characterized by three alpha domains, 
differently from the other isoforms which lack one or more globular domain. The 
most analyzed isoforms are HLA-G1 and HLA-G5 antigens. The proteolytical 
cleavage of surface isoform HLA-G1 generates the soluble HLA-G1 form (sHLAG1) 
[25]. 
An in frame termination codon in HLA-G exon 6 leads to a truncated cytoplasmic tail 
which is 19 amino acids shorter than the corresponding tails of HLA-A, -B and –C 
proteins. This feature prevents the signal transduction from the cell surface to the 
nucleus. However, the membrane-bound HLA-G can localize in lipid rafts and can 
act as a signaling molecule, via modification of the phosphorylation state of raft-
localized proteins [26].  
The HLA-G production up-regulation is controlled by interleukin (interleukin-10), 
interferon and hormone molecules [13]. 
Membrane-bound HLA-G1 and  soluble HLA-G (HLA-G5 and sHLA-G1) molecules 
exert immunosuppressive effects: (i) inhibit the cytotoxic activity of CD8 positive T 
lymphocytes (CTL) and Natural Killer (NK) cells [27], (ii) induce the apoptosis of 
NK and activated cytotoxic T cells [28], (iii) inhibit the allogeneic CD4 positive T-
cell proliferation and interfere with naïve CD4 T-cell priming [29], (iv) inhibit 
antigen presenting cell  and B lymphocyte differentiation [30], (v) induce regulatory 
T cells [31] (Figure 3). Furthermore, sHLA-G affects angiogenesis interacting with 
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endothelial cells [32] and induces resting NK cells to produce chemokines and 
cytokines [8]. 
The functions of HLA-G molecules are due to their ability to act as a ligand for 
different receptors expressed by immune cells (Figure 3). HLA-G interacts with NK 
receptor KIR2DL4 [8] and leukocyte inhibitory receptors (LILRs) / immunoglobulin-
like transcripts (ILT) [9] as LILRB1 (LIR-1/ILT2/CD85j), which is highly expressed 
on T and B lymphocytes and with LILRB2 (LIR-2/ILT4/CD85d), present mainly in 
monocytes/macrophages. The alpha3 domain of HLA-G is the putative binding site 
for ILT receptors [33] while the residues Met76 and Gln79 in the alpha1 domain play 
a critical role in the recognition of KIR2DL4 receptor [34]. 
Soluble HLA-G has potentially a higher range of activity than membrane-bound 
HLA-G. The circulating isoforms could bind to the same sets of leukocytes and 
perform exactly the same functions also systemically. 
The membrane-bound and soluble HLA-G proteins have monomer, dimer, and 
oligomer forms; the dimer seems to have a dominant effect on the LILRB signaling. 
Dimers of HLA-G have been observed on the surface of transfected cells [35], on 
choriocarcinoma cell line JEG-3 [36] and on first trimester trophoblast cells [37]. A 
disulfide-bonded dimer conformation is possible for the presence of a cysteine 42 
residue that is present only in the heavy chain α1 domain of HLA-G [33,35].  
Soluble HLA-G1 is able to inhibit endothelial cells through specific interaction with 
the CD160 molecule, a glycosylphosphatidylinositol-anchored, major 
histocompatibility complex (MHC) Class I-dependent, immunoglobulin-like 
receptor, that is expressed by activated endothelial cells [32] (Figure 3). This 
interaction seems to lead to apoptosis of endothelial cells required for normal 
placental development. 
HLA-G molecules undergo the trogocytosis mechanism: some effectors CD4 and 
CD8 T lymphocytes acquire immunosuppressive HLA-G1 molecules from antigen 
presenting cell membranes and reverse their function from effectors to regulatory 
cells [38]. 
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The HLA-G expression has been analyzed in different pathological conditions, such 
as transplantation, oncology, viral infections, inflammatory and autoimmune diseases 
indicating that HLA-G can favour graft tolerance, tumor cell and virally infected 
immune escape and control the inflammatory conditions [39].  
 
 
 
 
 
Figure 3. HLA-G receptors. HLA-G receptors expressed on immune (CD8 T and 
CD4 T cells, B cells, natural killer (NK) cell, macropages, dendritic cells) and 
endothelial cells. ILT: immunoglobulin-like transcript; KIR: killer inhibitory 
receptor; TCR: T cell receptor. 
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5. HLA-G and pregnancy 
Pregnancy is commonly considered a paradox. In an outbreed population, half of the 
fetal genes are paternal, thus the fetus may be considered a semi-allograft. However 
in normal pregnancy the maternal immune system does not reject the fetus, even if it 
is a “stranger in a strange land” [40], as a series of tolerogenic mechanisms are 
developed to allow gestation and birth of healthy babies. 
The enigma of the absence of fetal rejection was stated in 1953 by Sir Peter 
Medawar. He proposed the presence of protective mechanisms that could stimulate 
the tolerance in the mother [41]. Especially, the absence of HLA class I and II 
molecules modulation and the production of immuno-suppressant soluble molecules 
(progesterone, prostaglandine, transforming growth factor–B1, Interleukin-10) [42] 
by the fetal tissues strongly confirm the development at the feto-maternal interface of 
tolerogenic conditions. 
Recently a fundamental role in maintaining this tolerogenic condition has been 
proposed for HLA-G antigens. The soluble HLA-G molecules have been detected in 
the plasma of pregnant women with increased levels during the first trimester in 
comparison to non-pregnant women [43] (Table 1). On the contrary sHLA-G plasma 
levels decrease during the third trimester [44,45] while it has an impressive boost at 
delivery [46] probably deriving from the shedding of placental membrane-bound 
HLA-G molecules. 
sHLA-G concentrations in serum/plasma of pregnant women have been associated 
with clinical outcome. sHLA-G levels in plasma from women who subsequently 
develop preeclampsia, a potentially dangerous disorder of human pregnancy 
associated with utero-placental vascular defects [47], and/or intrauterine growth 
retardation (IUGR) are lower than those in control pregnant women, in the first, 
second [43,45] and third trimesters [48]. Women with in vitro fertlization (IVF) 
failure manifested by spontaneous abortion in the early pregnancy present lower 
sHLA-G in the pre-ovulation period and during pregnancy compared to women with 
normal pregnancies [49]. 
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 The reduction of HLA-G molecules could disregulate uterine natural killer (uNK) 
cells which are supposed to participate in the process of placentation and in uterine 
spiral artery transformation. Soluble HLA-G may contribute to trigger functional 
maturation of the uNK cells and vascular remodelling and decidualization. The 
reduced release of sHLA-G into the maternal circulation in preeclampsia and IUGR 
may alter the maternal-fetal immune relationship and thus be involved in the cause of 
these disorders.  
 
 
 
 
 
 
Table 1. Published studies of HLA-G expression in serum of normal and 
pathological pregnant women. 
PE: preeclampsia; IUGR: intrauterine growth retardation 
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Study 
(year) Sample Technique MoAb Results 
Normal condition 
Hunt JS 
Am J Obstet Gynecol 2000 
Serum 
44 non pregnant women 
129  pregnant women 
ELISA 16G1, 16A1  sHLA-G higher in pregnant women 
Hackmon R 
Fetal Diagn Ther. 2004 
Serum 
21 pregnant women 16-20 weeks 
19 women at term 
ELISA 87G, 16G1 sHLA-G lower toward term 
Yie SM  
Am J Obstet Gynecol (2005) 
Serum 
12 pregnant women first, second, third trimesters ELISA 4H84, 3C/G4 
sHLA-G decrease in third trimester 
pregnant women 
Steinborn A  
Am J Reprod Immunol (2007) 
Plasma 
40 non pregnant women 
291 pregnant women 
ELISA MEM-G9 sHLA-G increase in first trimester pregnant women 
Rizzo R 
Am J Reprod Immunol (2009) 
Plasma 
43 Pregnant women third trimester, at delivery ELISA MEM-G9 sHLA-G increase at delivery 
Pathological condition 
Pfeiffer KA 
Hum Immunol (2000) 
Serum 
65 IVF patients  preovulatorily, after a positive 
HCG test weekly until the 9th gestational week 
ELISA TP25.99 depletion W6/32 
sHLA-G decrease  in the pre-ovulation 
period and during pregnancy in women 
with a spontaneous abortion in IVF 
Yie SM  
Am J Obstet Gynecol (2005)  
Serum 
12 pregnant women and 12 PE women first, 
second, third trimesters 
ELISA 4H84, 3C/G4 sHLA-G decrease in first trimester preeclamptic women 
Steinborn A  
Am J Reprod Immunol (2007) 
Plasma 
40 non pregnant women 
291 pregnant women first, second, third trimesters 
236 PE/IUGR pregant women  first, second, third 
trimesters  
ELISA MEM-G9 sHLA-G decrease in second trimester preeclamptic women 
Hackmon R 
Am J Obstet Gynecol (2008) 
Serum 
24  pregnant women third trimester 
26 PE  pregnant women third trimester 
ELISA MEM-G9 sHLA-G decrease in third trimester preeclamptic women 
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5.1. HLA-G and trophoblasts 
The trophoblast differentiates into extravillous and villous tissues where extravillous 
cytotrophoblast (evct) cells invade the deciduas while villous cytotrophoblasts (vct) 
produce the outer villous syncytiotrophoblast (st) layer of chorionic villi (Figure 4). 
None of these villous trophoblast populations constitutively express HLA-A and -B 
at their surface. The absence of classical HLA class Ia molecules in cytotrophoblast 
cells, except for HLA-C, could activate NK cells towards fetal tissues. This is not the 
fact as the NK cells cytotoxicity is controlled by the interaction of HLA-C and HLA-
G molecules with inhibitory receptors. The HLA-C1 group interacts with inhibitory 
KIR receptors 2DL2 and 2DL3, while the HLA-C2 group interacts with 2DL1 
inhibitory receptor. HLA-G antigens interact with KIR2DL4 NK receptor [50] 
inducing proliferation and interferon (IFN)-γ secretion which might contribute to 
implantation and decidualization during early pregnancy [51]. 
HLA-G has been firstly detected in placenta by Ellis et al. [52] who have reported an 
HLA-G expression in chorionic membrane (extravillous) cytotrophoblast cells and  
in term amniochorion and trophoblast cells (Table 2). HLA-G has been observed in 
all types of extravillous cytotrophoblasts, with an increased gradient of expression 
from the villi into the deciduas [53]. Non-trophoblastic HLA-G expression has been 
detected in Hofbauer cells in the mesenchymal core of chorionic villi [54] and in 
endothelial cells [55]. An RNAse protection assay and quantitative RT-PCR studies 
have indicate that the full-length transmembrane form of HLA-G (HLA-G1) is the 
predominant splice variant transcribed in vivo by trophoblasts and it is mainly 
expressed as a disulphide-linked homodimer [37]. Soluble HLA-G might derive from 
transmembrane HLA-G1 molecules and from HLA-G5 transcript [56-58]. Some 
investigators have failed to report HLA-G5 in villous placenta [59] underlining some 
differences in the results obtained by different research groups. It is of interest the 
work by Ishitani et al. [56] and Le Maoult et al. [58] which have verified the presence 
of HLA-G5 isoform by blocking the staining with 16G1 monoclonal antibody 
(moAb) by the addition of the 20-mer synthetic peptide and using a new anti-HLA-
 16 
G5/-G6 moAb called 5A6G7 respectively. However these discrepancies are still to be 
resolved. 
The importance of HLA-G presence in placental trophoblasts is evident in 
preeclampsia (Table 2), that is characterized by a defect in placental membrane and 
soluble HLA-G expression [60,61], where the absence of HLA-G molecules has an 
effect on fetal protection and vascular events.  
 
 
 
 
 
Figure 4. HLA-G expression by cytotrophoblast cells in the early gestation. 
Placental villus, trophoblastic column, trophoblastic shell and deciduas are 
represented. HLA-G is expressed by invasive cytotrophoblast cells. 
 
 
Table 2. Published studies of HLA-G expression in trophoblast cells of normal and 
pathological pregnant women. 
Decidual vessel 
Invasive cytotrophoblasts (evct) 
Blastocyst 
Uterine epithelium 
Cytotrophoblast (vct) 
Syncitiotrophoblast (st) 
HLA-G 
Villus 
Colum
Shell 
Interstitia
Endo-
vascular 
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Study 
(year) Sample Technique MoAb Results 
Normal condition 
Ellis SA 
Immunology (1986) Amniochorion cytotrophoblast 
Immunoflorescence 
SDS-PAGE 
Isoelectric focusing 
W6/32 
BBM.1 
Novel HLA Class I molecule on 
chorionic cytotrophoblast cell membranes 
Ishitani A 
J Immunol (2003) 
First trimester placenta (5–12 wk of 
gestation) and normal term placentas 
(37–39 wk of gestation) 
ELISA 
Immunohistochemical staining 
Western analysis 
87G 
01G 
16G1 
Membrane HLA-G in extravillous 
trophoblasts, soluble HLA-G in all 
placental trophoblasts 
Morales PJ 
J Immunol (2003) First trimester and term placentas 
Immunohistochemical staining 
 
1-2C3 (G1) 
26-2H11 (G2) 
sHLA-G1 and m/s-G2 are produced in 
placentas 
m/sHLA-G2 present in the invasive 
trophoblast 
Blaschitz A 
Mol Hum Reprod (2005) 
Term placentas 
 
RT PCR 
Immunohistochemistry and 
immunocytochemistry 
ELISA 
Western blot analysis 
MEM-G/1 4H84 
Trophoblasts express only the HLA-G1 
isoform 
 
LeMaoult J 
Mol Hum Reprod (2005) 
First-trimester 
extravillous cytotrophoblast Immunohistochemistry 5A6G7 
HLA-G5 expressed by extravillous 
cytotrophoblasts 
Apps R 
Eur J Immunol  (2007) 
Decidual and placental 
tissues from first-trimester pregnancies 
Immunoblotting 
Flow cytometry 
G233 
87G 
MEM-G/11 
HLA-G - b2m-associated dimers expressed 
by trophoblasts 
Pathological condition 
Goldman-Wohl D 
Mol Hum Reprod  (2000) 
First, second trimesters and term 
placentas 
12 uncomplicated pregnant women 
10 PE pregnant women 
RNA in-situ hybridization NA HLA-G mRNA expression defective in 
most preeclamptic placentae 
Yie SM 
Am J Obst Gyn (2004) 
Term placentas 
14 uncomplicated pregnant women 
20 PE pregnant women 
 
Western Blot lysate 
 
4H84 Reduced HLA-G protein in PE placentas 
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5.2. HLA-G and embryo 
The first demonstration of HLA-G expression in preimplantation human embryos has 
been obtained by Jurisicova et al. [62] by RT-PCR and immunocytochemistry 
techniques (Table 3). The authors have shown the presence of a HLA-G heavy chain 
specific mRNA in about 40% of the 148 blastocystis tested. They have also reported 
that HLA-G mRNA is present in all preblastocyst development stages, including 2- to 
4-, 5- to 8-, and 9- to 16-cell embryos and morulas. The detection of HLA-G specific 
mRNA in preimplantation embryos has been confirmed by protein detection at cell 
membrane level and by an increased blastocystic cleavage rate when compared to 
embryos without HLA-G transcripts [63]. Yao et al. [64] have confirmed that human 
preimplantation embryos express HLA-G mRNA with some difficulties at the earliest 
stages but with an increasing proportion of positive embryos with developmental 
stage. The predominant isoform is HLA-G3 and -G4 while the full-length membrane 
bound (G1) and soluble forms (G5) and the truncated G2 and G6 vary in their 
expression, with G1 mRNA present in the 80% of blastocysts, soluble G5 in the 20% 
and soluble G6 in the 32%. Hunt et al. [65] have demonstrated that preimplantation 
human embryos express HLA-G5 but not HLA-G6 isoforms using specific HLA-G5 
and –G6 moAbs [57]. These results are in striking contrast with mRNA data 
supporting the hypothesis of a gestational post-trascriptional programming of HLA-
G isoforms. On the contrary Desoye et al. [66] have been unable to show a HLA-G 
staining on three unfixed polyploid embryos at the 2-, 5-, and 8-cell stages; Roberts 
et al. [67] have not detected HLA-G on three blastocysts and Hiby et al. [68] have 
found no HLA-G mRNA in 11 preimplantation embryos ranging from the 2 cell to 
the blastocyst stage using nested primers for full-length HLA-G. These contrasting 
data on HLA-G expression during the critical period of preimplantation embryonic 
development could be explained by differences in methodology and quality of the 
embryos used. Hiby et al. [68] have isolated mRNA from zona intact embryos with a 
standard phenol-chloroform extraction and a nested RT-PCR for full-length HLA-G 
with  the outside forward primer located at exon 3 and the reverse primer at 3’ UTR, 
the inside forward primer located at exon 5, and the reverse primer at 3’ UTR. These 
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primer sets cannot amplify HLA-G2 and -G3 isoforms because G2 lacks exon 3 and 
G3 lacks exon 3 and 4. On the contrary Yao et al. [64] have isolated mRNA with 
high performance magnetic beads removing the zona first. The quality of the 
embryos could be a possible reason for these different results. Yao et al. [64] have 
used only good-quality diploid embryos (grade A–C embryos and grade 4 
blastocysts), which was not the case in previous studies [66]. 
The discrepancies obtained with embryo immunostaining for HLA-G molecules 
could be explained by the differences in methodology and the quality of the embryos 
used. Previous studies have used unfixed [66], acetone fixed [67], and 
paraformaldehyde fixed embryos [62,63] and a primary Ab incubation time between 
30 min and 1 h. Yao et al. [64] and Shaikly et al. [69] have used the HLA-G-specific 
moAb MEMG/9 on fixed and permeabilized embryos, revealing both cytoplasmic 
and surface expression and prolonged overnight the Ab incubation  to increase the 
sensitivity of the technique.   
Shaikly et al. [69] have found a stronger HLA-G staining on the trophectoderm of 
blastocysts, reinforcing the hypothesis of an implication of HLA-G in early 
implantation of the embryo in the maternal uterus. 
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Table 3. HLA-G expression by preimplantation human embryos. 
 
 
 
Study 
(year) 
N.  
cultures 
N° positive 
embryos (%) Culture media Hrs post fertilization Detection Antibody Fixative 
Positive results 
Jurisicova A 
PNAS (1996) ND ND Ham’s F10  24-96 1B8 Paraformaldehyde fixed 
Yao YQ 
J Immunol (2005) 20 15 (75) IVF 24-144 MEM-G9 Fixed and permeabilized 
Shaikly VR 
J Immunol (2008) 11 8 (73) Sequential medium 48-72 MEM-G9 Fixed and permeabilized 
Negative results 
Desoye G 
J Immunol (1988) 3 0 Ham’s F 10  24-96 W6/32 Unfixed 
Roberts J 
Immunol (1992) 3 0 Earle’s solution 144-192 W6/32 Acetone fixed 
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The first non-invasive proof of non classical HLA-I expression by human early 
embryos was obtained in 1999 by Menicucci et al. [70]. They have demonstrated the 
presence of soluble HLA-G molecules (sHLA-G) in 90% of 8-cell stage embryo 
culture supernatants, obtained by ART. A significant association has been observed 
between HLA-G production and embryo cleavage rate. This study was confirmed by 
Fuzzi et al. in 2002 [71] (Table 4). The authors have presented the first in vivo proof 
of the role of HLA-G molecules in pregnancy implantation showing the presence of 
soluble HLA-G molecules in the supernatants from cultures containing one to four 
embryos. Two groups of patients have been identified on the basis of sHLA-G 
molecule presence or absence in the embryo culture supernatants. Although no 
clinical differences have been observed between the two groups, positive embryo 
implantation occurred only in women with sHLA-G molecules in embryo culture 
supernatants.   
This study started wide ranging research on this topic [72,73]. Further reports [69,74-
86] have analyzed the presence of sHLA-G molecules in the supernatants from single 
embryo cultures by enzymatic immunosorbent assay (ELISA) and HLA-G specific 
monoclonal antibodies (MEM-G1; MEM-G9; 4H84, 3C/G4). They have obtained a 
significant relationship between the secretion of these molecules by early embryos 
and a higher implantation/pregnancy rate with a significantly higher proportion of 
sHLA-G positive embryos developing to blastocysts in vitro [69,82].  The meta-
analysis of eleven studies evaluating sHLA-G in embryo culture for predicting 
pregnancy outcome in women undergoing ART has reported a modest diagnostic 
accuracy (DOR: 4.38 (95% CI, 2.93-6.55) while a subgroup analysis restricted to six 
studies with good quality embryos has shown an increase in the diagnostic 
performance (DOR: 12.67 (95% CI, 3.66-43.80)) [87]. These studies have 
investigated more than six thousand supernatants from single ART procedure 
embryos, with a recorded presence of sHLA-G from 36.2% [77] to 69.9% [80]. 
Shaikly et al. [69] have demonstrated a HLA-G specific labelling in the 50% of the 
twenty-four embryos analyzed with a distribution and intensity of fluorescence 
extremely variable.  
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Two main points should be focused on: (i) the presence of positive pregnancy 
outcomes also in sHLA-G negative samples. Sher et al. [75], Desai et al. [82] and 
Shaikly et al. [69] have reported significantly higher pregnancy rates when sHLA-G-
positive embryos have been transferred but they have evidenced a pregnancy rate of 
25-36% with sHLA-G-negative embryos. The absolute results of the first work by 
Fuzzi et al. [71], where all the positive pregnancies have been associated to sHLA-G 
positive embryo supernatants, could be ascribed to the presence of more embryos in 
each culture and/or to a different specificity of the detection assays. The different 
ELISA protocols used could account for different values and correlations of sHLA-G 
expression and implantation. Shaikly et al. [69] have confirmed the expression of 
sHLA-G in cleavage stage embryos during days 1 and 2 of human development but 
documented a marked variability of sHLA-G expression by early embryos from the 
same patient indicating a possible gestational embryo programming that could affect 
the results of sHLA-G and implantation correlation. However, sHLA-G-positive 
embryos have shown a higher rate of implantation in comparison with sHLA-G-
negative embryos; (ii) the presence of sHLA-G is not indicative of chromosome 
normality [69,82] as no significant differences have been observed in sHLA-G 
expression between embryos diagnosed as chromosomally normal or abnormal. For 
this reason sHLA-G detection in conjunction with current morphological parameters 
to identify embryo implantation potential is needed. 
In 2006 Ménézo et al. started a debate on the exact amount of sHLA-G produced by 
a single human embryo [88]. The authors have reported that human preimplantation 
embryo protein content is 45-50 ng with a consequent HLA-G release from 10 to 
100% and above the total protein content of the embryo considering the levels of 
sHLA-G molecules in embryo supernatants claimed in the literature. The human 
embryo is able to produce high amounts of other proteins such as human chorionic 
gonadotropine (hCG) that can be detected in the mother’s urine [89] suggesting a 
massive production at the feto-maternal interface. A possible explanation of this 
protein production could be found in the morphological and metabolic changes of 
preimplantation pluripotent embryonic cells:  
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(I) the cleavage stages are characterized by (i) a low metabolism, (ii) a high 
protein transduction rate and (iii) the necessity of exogenous pyruvate that are 
unusual features for any other mammalian somatic cell type [90];  
(II) matrix metalloproteinases, the main proteinases facilitating the process of 
embryo implantation and uterus extracellular matrix remodeling and degradation 
[91], are present at all stages of embryo development from the one-cell to the 
blastocyst. It is known that metalloproteases enhance HLA-G shedding [92] 
suggesting the increased secretion of HLA-G by pre-implantation embryo as a result 
of metalloprotease activation;  
(III) day-3 embryos cultured in vitro for 48 hours are able to secrete protein 
patterns similar to those of day-5 uterine blastocysts suggesting the in vitro 
culture is responsible for an accelerated embryo development and protein production 
[93].  
These observations should be considered in the evaluation of the ability of 
embryonic cells to produce proteins as they have unique features and necessity in 
comparison with the other cell phenotypes. Their possibility to survive in the uterus 
is connected with their ability to escape the maternal immune system. Hence the 
importance, in the implantation process, to sustain an extensive HLA-G production.   
Two studies [94,95] have failed to detect sHLA-G molecules in embryo culture 
supernatants underlining some discrepancies with other studies (Table 4). The 
authors that have observed positive sHLA-G embryo cultures have documented 
different percentages of positive supernatants (20-70%) and levels from 38 pg/ml to 
1890 ng/ml. Warner et al. [96] have reviewed the literature present in PubMed at the 
end of 2007. They found differences in the specificity and concentrations of capture 
and detection antibodies, in the characteristics of positive and negative controls, in 
the time and temperature of incubation. The embryo cultures, the time of collection 
and other clinical parameters were also compared. They have concluded that the 
presence of significant technical discrepancies could explain these contrasting 
results.  
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Some of the differences that should be taken into consideration when comparing 
these different studies are: (i) culture time; (ii) culture media; (iii) capture and 
detection antibodies; (iv) the standards (Table 4). 
The embryo culture time is in a range from 48 to 120 hrs post fertilization. This 
could explain at least in part the different levels of sHLA-G. The 48 - 72 hour culture 
period seems to be the best time points to detect sHLA-G in embryo supernatants and 
was selected in the majority of the studies. Where different culture time were used 
contrasting results as soluble HLA-G are predictable as secretion levels measured by 
ELISA may increase/decrease over time. 
Culture media are also important for in vitro embryo growth [97] and can be divided 
accordingly to their composition in four groups: (i) glucose and inorganic 
phosphate-free medium (P1, IVC-One); (ii) low-glucose medium (IVF, Sequential 
medium); (iii) glucose, gentamicin sulphate and protein-free medium (Human 
Tubal Fluid (HTF)); (iv) early cleavage medium (ECM). The different composition 
of these culture media could have influenced sHLA-G production. Culture media 
play an important role in determining whether the embryo potential can be realized 
[98] leading to epigenetic changes in the embryonic genome [99] and influence gene 
expression [98,100,101,102]. Rinaudo P and Schultz R [101] have observed that the 
expression of 114 genes, including genes involved in protein synthesis, cell 
proliferation and transporter functions, are affected in embryo after in vitro culture. 
Optimizing a culture medium in terms of its ability to promote embryo growth [103] 
seems to avoid certain postnatal developmental and behavioural consequences and 
imply that minor variations in the culture media can lead to differences on the 
resulting embryos. For example human tubal fluid (HTF) and preimplantation stage 
one (P1) culture media differ in fertilization rate, embryo quality, implantation and 
pregnancy rates. Artini et al. [104] have demonstrated that embryo fertilization rate 
with HTF was 58.6% while with P1 62.5% (P = 0.003), the HTF embryo quality was 
lower (15.4%) than P1 embryos (68.7%) (P = 0.002) as the implantation rate (HTF 
embryos 6.8% versus P1 embryos 12.2%) (P = 0.02) and the pregnancy rate (HTF 
embryos 17.1% versus P1 embryos 23.7%) (P = 0.02). The use of                   
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different culture media could have influenced the results obtained analysing sHLA-G 
production by early embryos.  
The discrepancy between the different ELISA systems may be related to a lack of 
specificity associated with cross-reactivity among capture and detection antibodies. 
Some of the MoAbs that have been used in these studies have presented cross-
reactivities: 4H84 MoAb has a cross-reactivity with HLA-Ia [105]; 5A6B MoAb 
seems to recognize the denaturated HLA-G heavy chain and to have an affinity also 
for other proteins; BFL.1 MoAb has a doubtful HLA-G specificity as it fails to react 
with HLA-G transfected cell lines [106]   
The positive standards could be subdivided into: cell culture purified molecules and 
recombinant proteins. These molecules could present a different structural 
conformation with a different antibody affinity that could affect MoAb recognition.  
 
 
 
 
 
 
Table 4. Soluble HLA-G expression by preimplantation human embryos.
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Study N. cultures N. Women N° positive 
cultures (%) 
sHLA-G 
range (ng/ml) Culture media 
Hrs post 
fertilization 
Capture 
Antibody 
Detection 
Antibody Standard 
Positive results 
Fuzzi B 
Eur J Immunol (2002) 
 
285 101 231 (26) 1.4 - 11 IVF 72 MEM-G9 
 (G1, G5) 
W6/32 biotin 
 
721.221G 
supernatant 
Roussev 
Fertil Steril (2003) >60 30 6 (20) ND P1 72 
MEM-G9  
(G1, G5) W6/32 biotin JEG3 supernatant 
Sher G 
Reprod Biomed (2004) 1245 201 101 (64) ND P1 72 
MEM-G9  
(G1, G5) W6/32 biotin JEG3 supernatant 
Yie SM 
Fertil Steril (2005) 386 137 270 (69.9) 10 - 1890 IVC One 72 
4H84   
(G1-G7) 3C/G4 
 
Purified HLA-G 
from placenta 
Desai N 
Reprod Biomed (2006) 712 83 309 (43) 3 - 10 HTF 72 
MEM-G9  
(G1, G5) W6/32 biotin Exbio standard 
Rebmann V 
Human Immunol (2007) 
 
588 
 
313 117 (20) 0.038 – 5.628 IVF 48, 72, 96 MEM-G9  (G1, G5) β2m Purified sHLA-G 
Fisch JD 
Fertil Steril (2007) ~2083 209 ND ND ECM 72 
MEM-G9  
(G1, G5) W6/32 biotin 
Human amniotic 
fluid 
Rizzo R 
J Reprod Immunol (2007) 50 38 26 (52) 1.2  - 13.1 IVF 72 
MEM-G9  
(G1, G5) β2m biotin 
721.221G 
supernatant 
Lédée N 
Am J Reprod Immunol 
(2007) 
Day 2: 309 
Day 3: 276 ND 
Day 2: 71 (23) 
Day 3: 188  (68) ND ND 48-72 ND ND ND 
Shaikly VR 
J Immunol (2008) 166 26 80 (50) 1.75 – 3.5 
Sequential 
medium 48-72 
MEM-G9  
(G1, G5) W6/32 biotin Exbio standard 
Negative results 
van Lierop MJ 
Mol Hum Reprod (2002) 15 ND 0 0 ND 48-120 
G233 (G1, G5) 
56B (G1, G4, 
G5) 
W6/32 (G1, G5) 
56B biotin 
BFL.1 biotin 
56B biotin 
Recombinant 
HLA-G1 
Sageshima N 
J Reprod Immunol (2007) 109 ND 0 0 ND ND 
MEM-G9  
(G1, G5) W6/32 biotin 
721.221G 
supernatant 
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5.3. HLA-G and oocyte 
A growing knowledge of human embryos obtained during through ART has not been 
paralleled by a similar knowledge of human oocytes, despite it being widely 
recognized that embryogenesis is deeply affected by oocyte quality. The main reason 
for this is probably that the selection for ART is applied to embryos in order to 
choose the best among them to be transferred in uterus. This widely practiced 
embryo selection has prevented the need to acquire skills in oocyte selection. In 
some countries, new laws and rules on ART need to move towards oocyte selection 
and to identify valid tools to recognize the best oocytes to be used for fertilization 
[107]. Currently oocyte selection is performed by using morphological parameters, 
without a clear association with a positive pregnancy outcome [108].  The 
development of non-invasive methods for oocyte selection could be an important 
step in all the ART laboratories. 
The oocyte quality is associated with early embryonic survival, the establishment and 
maintenance of pregnancy and fetal development. The quality and the developmental 
competence of an oocyte is acquired during the maturation process, during 
progressive differentiation throughout folliculogenesis. The ability of the oocyte to 
mature, be fertilized and to develop into a viable embryo starts with oocyte growth 
during the first steps of follicular development and goes on until the final oocyte 
capacitation. Ovarian cyclic activity induces some primordial follicles to grow, 
however, most of these follicles degenerate through atresia and in growing follicles, 
only a subset of oocytes are competent and able to support meiosis, fertilization and 
early embryo development to the blastocyst stage. Growing lines of evidence suggest 
that oocyte competence relies on the storage of messenger RNAs and proteins that 
will support early stages of embryo development, before full activation of embryonic 
genome. It is known that fertilized oocyte transcription is silenced in the early stages 
of embryo development and 90% oocyte maternal mRNAs degrade in the 2 cell 
stage. The store of proteins in the fertilized oocyte is sufficient to support embryo 
development to the 8 cell stage until the activation of the embryonic genome [109]. 
The recent discovery of oocyte secreted factors and of their ability to regulate 
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surrounding somatic cells suggests a central role of the oocyte in the success of 
folliculogenesis [110]. 
The follicle activation is a fundamental event for the oocyte maturation and it is 
controlled by a fine tuning of inhibitory and stimulatory soluble factors. The 
follicular fluid represents the essential and specific microenvironment for the 
regulation of the ovary function and oocyte maturation [111] and a possible 
relationship has been proposed between specific follicular fluid components (sFas-
sFas ligand system, TNF-alpha, Nitric oxide, Hyaluronan, Gelatinases) and ART 
outcome [112].   
Rizzo R et al. [85] have analyzed sHLA-G molecules in the follicular fluids (FFs) 
and have found a significant correlation between sHLA-G presence in FFs and in the 
culture supernatants of the corresponding fertilized oocytes (Figure 5). Lédée et al. 
[86] and Shaikly et al. [69] have confirmed the presence of sHLA-G molecules in 
FFs in 96% and 47% respectively but they have failed to identify a correlation with 
early embryo sHLA-G production (Table 5). Several differences in embryo culture 
conditions and the technical procedures could explain the differences in the 
correlation results. The presence of sHLA-G in FFs is not a confirmation that it is 
important in oocyte maturation but the presence of HLA-G molecules in follicular 
fluids suggests the possible role of this antigen in the oocyte maturation process. 
Further studies are required to confirm the relationship between FFs and embryo 
sHLA-G production.    
Rizzo et al. [85] and Shaikly et al. [69] have identified granulosa cells as producers 
of HLA-G molecules (Figure 5), while there are conflicting results on HLA-G 
protein expression by oocytes. Desoye et al. [66] have found no staining on three 
unfixed oocytes, while Roberts et al. [67] have found 2 of 11 to be positive and 
Jurisicova et al. [62,63] have shown a positive staining of 21 out of 33 oocytes. These 
findings have been confirmed by the presence of HLA-G mRNA in 17 of 21 pools of 
5-8 unfertilized oocytes [62,63].  
The possible implication of HLA-G molecules on oocyte maturation has been 
evaluated by Rizzo et al. [113] (Figure 5). They have analyzed the culture 
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supernatants of 152 oocytes matured in vitro for sHLA-G presence. The in vitro 
oocyte maturation procedure has allowed the analysis of sHLA-G production by the 
cumulus-oocyte complex (COC) without the influence of the in vivo maternal 
microenvironment. The cumulus oophorus is characterized by the granulosa cells 
which surround the mammalian oocyte. These cells create a structural pathway for 
cell-to-cell communication where cumulus cells provide several trophic factors to the 
preovulatory oocyte [114]. Several results indicate that the measurement of gene 
transcription levels in cumulus cells would reliably complement the morphological 
oocyte evaluation providing a useful tool for selecting oocytes with greater chances 
to be fertilized [115,116]. 
Rizzo et al. [113] have demonstrated the the COCs produce sHLA-G molecules 
during oocyte maturation process. The main point is that no sHLA-G molecules have 
been detected in the COC culture supernatants corresponding to immature COCs 
while the highest sHLA-G production has been shown in good grade COCs. Some 
maturated COCs have failed to secrete sHLA-G, underlining that sHLA-G is only 
one of the factors implicated in this process. Further studies are necessary to confirm 
the possible role of HLA-G molecules in oocyte maturation and to evaluate if HLA-
G could be a marker of oocyte quality. 
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Figure 5. HLA-G expression in mature follicle. HLA-G molecules are present in 
follicular fluid as evidenced by Western Blot analysis with MEM-G9 moAb (G1, G5: 
positive controls; FF1, FF2: follicular fluid; FO1, FO2: fertilized oocyte; HeLa: 
negative control) [85], in granulosa cells and polymorphonuclear cells as 
demonstrated by immunocytochemistry with MEM-G9 moAb [85] and in cumulus-
oocyte complex as shown by Western Blot analysis with MEM-G9 moAb (+: 
positive control, -: negative control; O1, O2: cumulus-oocyte complex) [113].  
Antrum 
Cumulus-oocyte complex 
Follicular Fluid 
Granulosa cells 
Polymorphonuclear-like cell 
Follicle  
From Rizzo R et al 2007 [85] From Rizzo R et al 2009 [113] 
HLA-G 
From Rizzo R et al 2007 [85] 
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Table 5. Soluble HLA-G expression in follicular fluids (FFs) and by the corresponding preimplantation human embryos. 
 
 
 
Study N. FFs N. Women 
N° positive 
embryo cultures 
(%) 
sHLA-G 
range 
in embryo 
(ng/ml) 
N° positive 
FFs (%) 
sHLA-G 
range 
in FFs 
(ng/ml) 
Culture 
media 
Hrs post 
fertilization 
Capture 
Antibody 
Detection 
Antibody Standard 
Rizzo R 
J Reprod Immunol (2007) 50 38  26 (52) 1.2  - 13.1 19 (38) 12.8-162.0 IVF 72 
MEM-G9 
 (G1, G5) β2m biotin 
721.221G 
supernatant 
Lédée N 
Am J Reprod Immunol (2007) 117 ND 
Day 2: 20 (23) 
Day 3: 58 (68) ND 82 (96) ND ND 48 - 72 ND ND ND 
Shaikly 
J Immunol (2008) 60 12 13 (21) 1.75 – 3.5 29 (47) 1.75-4.0 IVF 72 
MEM-G9  
(G1, G5) 
W6/32 
biotin Exbio standard 
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6. Expected HLA-G impact in ART 
Currently, different approaches are used to select oocytes and embryos for ART 
procedures, but they do not assure a significant association with the pregnancy 
outcome. 
Several studies have analyzed the possible implication of HLA-G molecules in the 
selection of embryos and oocytes for ART. Further analysis and novel approaches 
are necessary to overcome the contrasting results obtained by different researchers 
[117]. The possible use of HLA-G antigens as a marker for oocyte and embryo 
selection is auspicable as it could firstly increase the chances of success with ART, 
secondly allow the selection of the best oocyte/embryo to transfer so reducing the 
number of transferred embryos and hence the incidence of multiple pregnancies. 
 
 
7. Expert commentary 
Further research is needed to evaluate the potential of sHLA-G as a marker of 
oocyte/embryo competency and to provide definitive proof that soluble HLA-G 
molecules are secreted by early embryos. Clearly the analysis of HLA-G molecules 
has to be improved given the contrasting results obtained in trophoblasts cells [59]. 
Unfortunately, it is not currently possible to measure HLA-G mRNA and membrane-
bound protein in the same oocyte/embryo, which would help to clarify these issues. 
The possible approach could be: 
 (i) a multicentre study where different laboratories could compare their results 
on the same samples. 
Several technical workshops have been organized in 2000, 2003 and 2004 to validate 
tools and protocols for HLA-G analysis [118,119] and laboratories are trying to agree 
standardization, in accordance with the Essen workshop in 2004 and the EMBIC 
Workshop on  sHLA-G and Embryo Implantation in Oxford (June 2008). 
 (ii) the use of different techniques  to confirm both positive and negative results. 
Several researchers are trying to develop new tools to analyze HLA-G molecules. 
Rizzo et al. [85] have proposed a cytofluorimetric assay to detect rapidly sHLA-G 
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molecules; recently Rebmann et al. [83] have established a rapid detection assay 
based on Luminex technology, allowing sHLA-G quantification in sample volumes 
of only 10µl within 1.5 hours. These techniques could be an important improvement 
in order to increase the specificity and sensitivity of sHLA-G detection assays.  
Further studies need to answer to the following questions: (i) What are the functions 
of sHLA-G during ooyte maturation and embryo implantation?, (ii) Why do some 
preimplantation embryos secrete sHLA-G and others not?, (iii) Where do sHLA-G 
molecules in FFs come from? 
 
 
8. Five-year view 
Much remains to be learned about the expression, regulation and functions of HLA-
G gene products at the junction of fetal and maternal tissues. Cellular sources remain 
unclear and target cells are still not well defined.  
How the semi-inflammatory conditions of the maternal–fetal interface might 
influence HLA class Ib gene expression is unknown. The functions of these antigens 
at the interface, during the embryo implantation and oocyte maturation remain to be 
precisely defined. 
Despite these uncertainties, much progress has been made. It now seems likely that 
HLA-G is not simply an evolutionary remnant but is, instead, a major player in the 
establishment of an appropriate immunologic state for semiallogeneic pregnancy.  
Despite the considerable progress in HLA-G detection there are some problems in its 
analysis in oocyte/embryo culture supernatants. 
Nowadays it is still mandatory to evaluate oocyte/embryo morphological parameters 
as  research should confirm the role of HLA-G molecules in oocyte/embryo 
development. 
The value of sHLA-G molecules as a marker of oocyte/embryo competency is 
extremely important as, in contrast with other techniques such as Pre-Implantation 
Genetic Diagnosis (PGD), this test is performed in a completely non-invasive way by 
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removing a small amount of the culture media surrounding two- and three-day-old 
embryos, and testing for sHLA-G. 
The sHLA-G molecule is a research response to the need of a rational basis to select 
few and possibly single competent oocyte/embryo at a time, while maintaining 
optimal ART success rates. 
Discovery of additional molecular markers [120] of oocyte/embryo competency and 
health will improve the potentiality of these non-invasive methodologies with wide 
possibilities for research and therapeutic application. 
The future of ART will be to combine morphologic evaluations with a biochemical 
assessment of molecules that represent a marker of oocyte/embryo competency. The 
expected impact will be to increase the pregnancy rates that will be possible when 
the success rates will achieve a high quality value using these approaches and the 
detection of these molecules will be no more questionable.  The ART laboratories 
could use morphologic parameters and biochemical markers for single embryo 
transfer, reducing the risk of multiple pregnancies. 
However further research is needed to identify the real oocyte/embryo competence 
markers. HLA-G molecules could be one of them but it is mandatory to improve a 
standardized detection in order to obtain comparable results prior to use HLA-G as a 
oocyte/embryo selection marker. 
 
 
Key issues 
• Currently it is difficult to determine the more appropriate oocyte/embryo for 
transfer in ART protocols  
• sHLA-G detection in oocyte/embryo culture supernatants could be a non-
invasive method to determine oocyte/embryo quality 
• Embryos with sHLA-G production are more likely to result in a successful 
implantation 
• sHLA-G detection in embryo culture supernatants should be further analyzed 
to identify the possible role as marker for embryo selection 
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• Possible correlation between sHLA-G detection in follicular fluids and in the 
corresponding fertilized oocyte  
• sHLA-G detection in follicular fluids should be further analyzed to identify 
the possible role as marker for oocyte selection 
• Possible correlation between sHLA-G detection in mature COCs  
• sHLA-G detection in COC supernatants should be further analyzed to 
identify the possible role as marker for oocyte maturation 
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Abstract 
Background 
Assisted reproduction technique (ART) pregnancy rates have not changed in recent 
years and an increased risk of twins, triplets or higher order pregnancies leads to a 
perinatal mortality and morbidity. Studies have therefore involved the identification 
of non-invasive methods to determine the oocyte/embryo quality allowing fewer 
embryos to be transferred while maintaining or improving pregnancy rates.  
In order to increase the chance of a successful pregnancy, the most viable embryos 
must be transfered but current knowledge of suitable biochemical markers that could 
predict the viability of embryos is extremely limited. The selection of embryos to be 
transferred is conducted using morphological aspects, cleavage speed and 
development appearance. This embryo scoring system could help in selecting the 
best embryo for transfer but it has limited ability to predict the implantation potential 
of individual embryos. The clinical challenge is to establish a marker of  embryo 
competency that could increase the pregnancy rate following ART and reduce the 
number of multiple pregnancies. 
Successful implantation in the human is dependent on the early embryo ability to 
avoid the maternal immune system. The fetus is considered a semi-allograft but, in 
normal pregnancies, it is not rejected by the maternal immune system. The presence 
of a complex signalling system, with molecules passing from the conceptus to the 
mother throughout pregnancy, is appealing and embryo suppressor factors 
responsible for early implantation have been proposed. One of the key protective 
mechanisms is thought to be the expression of non classical HLA class I HLA-G 
molecules by trophoblasts. Due to its importance in reproductive immunology it has 
been considered a possible marker for oocyte/embryo selection.  
The HLA-G gene is located at the telomeric part of the 6p21-3 chromosomal region, 
near the HLA-A locus. It exhibits the typical structure of a classical HLA class I gene 
with a similar exon/intron organization. The HLA-G antigen has some characteristics 
that differentiate it from classical HLA class I antigens. The HLA-G molecule has a 
restricted tissue distribution, being expressed in physiological conditions by 
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cytotrophoblasts and thymus. The allelic polymorphism is limited to 36 alleles. The 
HLA-G gene is characterized by a 14 base pair insertion/deletion polymorphism 
(rs16375) in exon 8 in the 3’ untranslated region (UTR) that is associated with 
mRNA stability and HLA-G protein expression. The allele with an insertion of 14 bp 
has been associated with lower levels of HLA-G expression than the allele with the 
14 bp deleted. Seven different HLA-G transcriptional isoforms, derived from mRNA 
splicing, have been described. Four of these encode membrane-bound products 
(HLA-G1, -G2, -G3, -G4), the other three soluble proteins (HLA-G5, -G6, -G7). It is 
well known that the biological functions of the classical HLA-class I and class II 
molecules are related to the complex mechanism of antigen recognition. The high 
polymorphism of the HLA structures represent a guarantee for the development of an 
efficient response against different viral and bacterial antigens whilst the elevated 
number of alleles is responsible for the allogeneic response resulting in the rejection 
of transplanted organs. HLA class Ia and HLA class II genes are totally unexpressed 
in cytothrophoblast cells preventing the consequential development of a 
semiallogenic response of the maternal CD8 positive T cells. However, the absence 
of HLA-Ia molecules would enhance the natural killer (NK) mediated cell 
cytotoxicity that is normally inhibited by the presence on target cells of the classical 
HLA-I determinants. The modulation of HLA-C and the nearly monomorphic HLA-
G molecules by invasive cytotrophoblasts prevents the allogeneic response and 
maintain a tolerogenic microenvironment. Membrane-bound HLA-G1 and soluble 
HLA-G (HLA-G5 and sHLA-G1) molecules exert immunosuppressive effects: (i) 
inhibit the cytotoxic activity of CD8 positive T lymphocytes (CTL) and NK cells, (ii) 
induce the apoptosis of NK and activated cytotoxic T cells, (iii) inhibit the allogeneic 
CD4 positive T-cell proliferation and interfere with naïve CD4 positive T-cell 
priming, (iv) inhibit antigen presenting cell and B lymphocyte differentiation, (v) 
induce regulatory T cells. sHLA-G affects angiogenesis interacting with endothelial 
cells and induces resting NK cells to produce chemokines and cytokines [1]. The 
functions of HLA-G molecules are due to their ability to act as a ligand for different 
receptors expressed by immune cells. HLA-G interacts with NK receptor KIR2DL4 
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and leukocyte inhibitory receptors (LILRs) / immunoglobulin-like transcripts (ILT) 
as LILRB1 (LIR-1/ILT2/CD85j), which is highly expressed on T and B lymphocytes 
and with LILRB2 (LIR-2/ILT4/CD85d), present mainly in monocytes/macrophages. 
Aim 
This thesis reports on several studies of the HLA-G molecule and its implication in 
pregnancy and embryo implantation. 
Methods and Results 
The analysis of the soluble HLA-G (sHLA-G) levels in lypopolysaccharide (LPS)-
activated peripheral blood mononuclear cell (PBMC) cultures from healthy subjects 
has revealed no differences between the three HLA-G insertion/deletion 14 bp 
genotypes (+14/+14 bp, -14/+14 bp, +14/+14 bp), while higher concentrations of 
interleukin (IL)-10, the main up-modulator of HLA-G production, have been 
observed in the +14/+14bp LPS-PBMC cultures [2]. Our data support the hypothesis 
of a feed-back loop mechanism between HLA-G and IL-10 molecules, which 
sustains their production. The -14/-14 bp and -14/+14 bp HLA-G samples with a -
477 G/G single nucleotide polymorphism (SNP) genotype in the 5’ upstream 
regulatory region (5’URR) of the HLA-G gene have presented a higher IL-10 
concentration in LPS-PBMC cultures. These observations could indicate that the –
477 SNP might have an independent impact on IL-10 concentration and that the 
differences are not only a consequence of linkage disequilibrium between the G -477 
SNP polymorphism and the -14 bp 3’UTR polymorphism. -477 SNP polymorphism 
is located very close to a putative heat shock element (HSE) and could influence the 
binding of the heat shock factor 1 (HSF1) leading to differences in IL-10 and sHLA-
G expression. 
The levels of sHLA-G are increased in the plasma samples of pregnant women 
during the first trimester in comparison to non-pregnant women. On the contrary 
sHLA-G plasma levels decrease during the third trimester while it has an impressive 
boost at delivery [3]. We have analyzed sHLA-G and IL-10 levels in the plasma 
samples of 43 women (15 non-allergic, 28 allergic) during third trimester, at delivery 
and 2 years after pregnancy. A significant increase in sHLA-G and IL-10 levels has 
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been documented at delivery regardless of the allergic status, however, allergic 
women have shown lower sHLA-G concentrations in comparison with non-allergic 
women. The reduced sHLA-G levels have not been caused by deficient IL-10 
production, as allergic and non-allergic women  presented equal amounts at all three 
time points investigated. This indicates that other factors involved in sHLA-G 
production and/or regulation differ between these two groups of women. It is 
possible that the Th2 cytokine microenvironment present in an allergic individual 
differently influences the sHLA-G secretion. Two years after pregnancy, the two 
groups have presented equal levels as the allergic women seem to experience a prime 
during pregnancy that is still evident two years after pregnancy, suggesting the 
presence of immunological changes imposed by pregnancy and still evident two 
years after labour. Our data have demonstrated that sHLA-G1 molecules are the most 
frequent isoform in plasma (75-80%) in both allergic and non-allergic women during 
labour. As sHLA-G1 molecules are mainly originated by metalloproteinase (MMP)-
dependent shedding at post-translational level of the membrane antigens, it could be 
hypothesized that sHLA-G1 could derive from the placenta disruption during  labour 
that is characterized by an increase in MMP-9 amounts.  
Several data have suggested an important role for HLA-G molecules in the survival 
of human embryos. HLA-G expression has been documented not only on trophoblast 
cells but also in preimplantation human embryos. Jurisicova et al. [4] have shown 
HLA-G heavy chain specific mRNA in about 40% of the 148 embryos tested. HLA-
G proteins at 2-cell stage and an increased embryo cleavage rate when compared to 
the embryos without HLA-G transcripts were detected. These results propose a 
variable expression of HLA-G during the critical period of preimplantation 
embryonic development. In order to have an in vitro and non-invasive system to 
analyze embryo behaviour towards sHLA-G production, an in vitro fertilization 
protocol was used, where the oocytes are fertilized in vitro and the embryos are 
transferred to the woman 2-3 days after fertilization. This allowed the analysis of the 
embryo culture supernatants for sHLA-G presence by a specific immunoenzymatic 
assay. In 2002  the first in vivo confirmation of the pivotal role of HLA-G molecules 
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in embryo implantation was presented [5]. The presence of sHLA-G molecules in 
285 supernatants from cultures containing one to four embryos obtained from ART 
has been analyzed. Although no clinical differences have been observed between the 
women, positive embryo implantation occurred only in women with sHLA-G 
molecules in embryo culture supernatants (p= 2.56×10–3, Fisher’s exact p test). This 
is the first observation made in humans to prove the importance of HLA-G 
expression in embryo implantation. In 2004 the analysis of sHLA-G molecules in 
supernatants from 318 single embryo cultures was presented [6]. We have confirmed 
a significant relationship between the secretion of these molecules by an early 
embryo and a higher implantation rate (p= 0.045, Mann-Whitney U test). These data 
propose the sHLA-G analysis in embryo supernatants as a useful marker, together 
with morphological characterization, for the selection of  embryos to be transferred. 
Since 2002 up to six thousand supernatants from single ART procedure embryos 
have been analyzed for sHLA-G presence. Discrepancies in the embryo culture 
protocol and the sHLA-G detection systems have not yet allowed the importance of 
sHLA-G as an embryo quality marker to be confirmed and studies are still needed to 
standardize the procedures to sustain the data obtained [7,8]. 
No hypotheses have yet been advanced on the absence of HLA-G expression in a 
percentage of early embryos obtained by ART. The presence of germinal defects or 
an impaired IL-10 secretion can be hypothesized. The presence of sHLA-G in the 
supernatants of single embryo cultures from couples admitted to a second 
fertilization procedure has been analyzed. These couples have previously shown a 
complete absence of sHLA-G in the first cycle embryo supernatants (0/31) [9]. The 
results obtained in the second in vitro fertilization cycle have shown some embryo 
supernatants positive for HLA-G (14/40), suggesting that the previous lack of 
antigen modulation is independent of germinal defects. The levels of IL-10 in the 
same embryo culture supernatants have been also investigated. No associations have 
been observed between the presence of IL-10, the production and levels of sHLA-G 
and pregnancy outcome. These results indicate that the lack of sHLA-G production 
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in some early embryos is not related to germinal defects or IL-10 impairment and 
suggest a gestational programming of sHLA-G secretion. 
Several ethical and legislative problems are increasing the necessity to reduce also 
the number of fertilized oocytes. Nowadays the oocyte selection is mainly performed 
by intra and extracytoplasmic morphological characteristics, but no data documents a 
clear association between the morphology and implantation outcome. The oocyte 
ability to mature, be fertilized and to develop into a viable embryo starts with oocyte 
growth during the first steps of follicular development and goes on until the final 
“oocyte capacitation” that seems to rely on the storage of messenger RNAs and 
proteins that will support early stages of embryo development, before full activation 
of embryonic genome. It is known that in the early developmental stage of the 
fertilized oocytes the transcription is silenced and the activation of the human 
embryonic genome starts between the 4- and 8-cell stages, approximately 70 hours 
after fertilization. Follicular fluid (FF) represents a specific microenvironment for 
oocyte maturation and a possible relationship has been proposed between specific FF 
components and ART outcome. 50 FFs were analyzed for sHLA-G molecule 
presence [10] and detectable sHLA-G molecules were observed in 31.2% FFs. To 
investigate the possible functional significance of sHLA-G molecules in FFs, we 
have related the sHLA-G in FFs and in the corresponding 4-8-cell early embryos. 
This analysis has shown a significant relationship between sHLA-G presence in FFs 
and in the corresponding embryo culture supernatants (p= 1.3x10-6; Fisher exact p 
test).  These results could suggest the analysis of sHLA-G in FFs as a reliable and 
non-invasive tool for oocytes selection to obtain embryos with an elevated ability to 
modulate HLA-G expression and consequently a higher implantation rate. Granulosa 
cells and the polymorphonuclear population have been identified as sHLA-G 
producers but because of ethical problems it was not possible to characterize the 
oocyte. 
In order to confirm that sHLA-G is involved in oocyte maturation, 152 in vitro 
maturated oocytes were analyzed of which culture supernatants could be 
characterized for sHLA-G presence without the influence of the maternal 
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microenvironment [11]. Our results have demonstrated that the cumulus-oocyte 
complex (COC), characterized by the surrounding granulosa cells and the oocyte, 
produces sHLA-G. The sHLA-G molecules were present in 19% of mature COC 
culture supernatants. On the contrary no sHLA-G molecules have been detected in 
the culture supernatants from immature COCs (p= 8.4 x 10-5; Fisher exact p test). 
These results show, for the first time, the ability of mature COCs to produce sHLA-G 
antigens that seem to be a marker for oocyte maturation.  
Conclusions 
Further research on HLA-G and pregnancy to evaluate the possible correlation 
between the oocyte and the corresponding embryo sHLA-G production and to 
confirm the value of sHLA-G as a marker of oocyte/embryo competency is required. 
Work is also necessary to improve standardization of sHLA-G detection in order to 
obtain comparable results prior to use HLA-G as an oocyte/embryo selection marker. 
The sHLA-G molecules is a research response to the need for a rational basis to 
select few and possibly a single competent oocyte/embryo each time, while 
maintaining optimal ART success rates. The future of ART foresees the combination 
of morphologic evaluations with a biochemical assessment of molecules that 
represent a marker of embryo competency. 
Future identification of additional molecular markers of oocyte/embryo competency 
and health can improve these non-invasive methods and their research and 
therapeutic potential. The culture supernatants of 39 immature and 73 mature COCs 
and the corresponding preimplantation embryos for the presence of proteins involved 
in inflammation, including several cytokines, chemokines (IL-1β, IL-1rα, IL-2, IL-4, 
IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (P70), IL-13, IL-15, IL-17, Basic FGF, 
Eotaxin, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1 (MCAF), MIP-1α, MIP-1β, PDGF-
BB, RANTES, TNF-α, VEGF) and soluble intercellular adhesion molecule 1 
(sICAM-1) have been analyzed [12]. The proteins present in the supernatants were 
sICAM-1 and IL-1rα, however, only sICAM-1 was expressed at high levels. The 
sICAM-1 release is very high in immature COCs, decreases in mature COCs (p < 
0.0001, Student t Test) and become even lower in preimplantation embryos (p < 
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0.0001, Student t Test). No significant differences have been observed in sICAM-1 
levels between immature oocytes with different morphological characteristics. On 
the contrary, the high grade mature COCs have presented the lower sICAM levels. 
sICAM-1 seems to have a clear tendency to decrease from immature to mature COCs 
and to fertilized embryos and it could be a possible biochemical marker for COC 
maturation and grading. 
In the future ART laboratories may be able to use morphologic parameters and these 
non-invasive biochemical markers for single embryo transfer, so reducing the risk of 
multiple gestation and increasing the pregnancy rate. 
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Riassunto (Abstract in Italian) 
Introduzione 
Nonostante gli importanti sviluppi della procedura di riproduzione medicalmente 
assistita (ART), la percentuale di gravidanze ottenute non ha subito modifiche negli 
ultimi anni ed il rischio di parti gemellari e multipli con una conseguente mortalitá e 
morbiditá perinatale è rimasto invariato. Come conseguenza, numerosi studi sono 
attualmente coinvolti nell’identificazione di metodi non invasivi per determinare la 
qualitá dell’oocita/embrione al fine di consentire il trasferimento di un numero 
ridotto di embrioni, mantenendo o incrementando la percentuale di gravidanze 
ottenute.    
Al fine di aumentare la probabilitá di ottenere un esito positivo della gravidanza, 
sarebbe necessario trasferire l’embrione maggiormente vitale. Attualmente, la 
conoscenza di marcatori biochimici, che possano essere utilizzati per predire la 
vitalitá embrionale, é estremamente limitata. La selezione degli embrioni da 
trasferire é effettuata sulla base di aspetti morfologici, di sviluppo e di velocità di 
clivaggio, con una limitata capacitá nel predire il potenziale di impianto del singolo 
embrione. Il traguardo della clinica è di stabilire un marcatore di competenza 
embrionale che possa incrementare la percentuale di gravidanze ottenute in seguito a 
procedura ART riducendo il numero di gravidanze multiple.  
La capacitá dell’embrione di evitare il sistema immunitario materno è alla base 
dell’impianto nell’utero materno. Il feto é considerato un trapianto semi-allogenico 
che durante una normale gravidanza non viene rigettato dal sistema immunitario 
materno. La presenza di un complesso sistema di segnali tra il feto e la madre 
supporta l’esistenza di fattori soppressori embrionali responsabili dell’impianto. Uno 
dei meccanismi chiave della protezione sembra essere l’espressione di molecole non 
classiche HLA (Antigene leucocitario umano) di classe I HLA-G da parte dei 
trofoblasti. Considerando la sua importanza nell’ambito della riproduzione si è 
ipotizzato un suo possibile ruolo come marcatore per la selezione 
oocitaria/embrionale. 
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Il gene HLA-G é localizzato nella porzione telomerica della regione cromosomica 
6p21-3, adiacente al locus HLA-A. Presenta un’organizzazione di esoni/introni simile 
a quella dei geni classici HLA di classe I. L’antigene HLA-G è caratterizzato da 
alcune peculiaritá che lo differenziano dagli antigeni classici HLA di classe I. Le 
molecole HLA-G hanno una ristretta distribuzione tissutale, con espressione da parte 
di citotrofoblasti e cellule timiche in condizioni fisiologiche. Il polimorfismo allelico 
è limitato a 36 alleli. Il gene HLA-G é caratterizzato da un polimorfismo di 
inserzione/delezione di 14 paia di basi (rs16375)  a livello dell’esone 8 nella regione 
3’ non tradotta (UTR) che è associato alla stabilitá del mRNA ed all’espressione 
proteica di HLA-G. L’allele con l’inserzione di 14 bp presenta livelli di espressione 
di HLA-G  inferiori rispetto all’allele con le 14 bp delete. Sono state descritte sette 
isoforme trascrizionali dovute a splicing alternativo del mRNA. Quattro di queste 
sono molecole associate alla membrana (HLA-G1, -G2, -G3, -G4), le altre tre sono 
proteine solubili (HLA-G5, -G6, -G7). E’ noto come le funzioni biologiche delle 
molecole classiche HLA di classe I e di classe II siano associate al complesso 
meccanismo di riconoscimento antigenico. In questo contesto l’alto polimorfismo 
delle strutture HLA garantisce lo sviluppo di un’efficiente risposta contro diversi 
antigeni virali e batterici. D’altra parte, l’elevato numero di alleli è responsabile dello 
sviluppo di una risposta allogenica risultante nel rigetto degli organi trapiantati. I 
geni HLA di classe Ia e di classe II non sono espressi dai citotrofoblasti prevenendo 
il conseguente sviluppo di una risposta semiallogenica da parte delle cellule materne 
T CD8 positive. Al contrario, l’assenza di molecole HLA-Ia attiverebbe la 
citotossicitá mediate dalle cellule natural killer (NK), normalmente inibite dalla 
presenza di determinanti classici HLA-I sulla superficie delle cellule bersaglio. La 
modulazione di molecole HLA-C e HLA-G da parte dei citotrofoblasti invasivi 
previene la risposta allogenica e mantiene un microambiente tollerogenico.  Le 
molecole HLA-G1 di membrana e solubili HLA-G (HLA-G5 e sHLA-G1) esercitano 
effetti immunosoppressivi: (i) inibiscono l’attivitá citotossica dei linfociti T CD8 
positivi (CTL) e delle cellule NK, (ii) inducono l’apoptosi di cellule NK e T 
citotossiche attivate, (iii) inibiscono la proliferazione allogenica dei linfociti T CD4 
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positivi ed interferiscono con la maturazione delle cellule T naïve CD4 positive, (iv) 
inibiscono le cellule presentanti l’antigene ed il differenziamento dei linfociti B, (v) 
inducono le cellule T regolatorie. Inoltre, sHLA-G interviene nell’angiogenesi 
attraverso le cellule endoteliali e la produzione chemochine e citochine da parte delle 
cellule NK [1]. Le funzioni delle molecole HLA-G risiedono nella loro capacitá di 
agire da ligandi di recettori espressi dalle cellule del sistema immunitario. HLA-G 
interagisce con il recettore delle cellule NK KIR2DL4 e con i recettori inibitori dei 
leucociti (LILRs) / trascritti immunoglobulin-like (ILT) come LILRB1 (LIR-
1/ILT2/CD85j), altamente espresso dai linfociti T e B e LILRB2 (LIR-
2/ILT4/CD85d), presente prevalentemente nei monociti/macrofagi. 
Scopo 
Questa tesi riporta diversi studi relativi alla molecola HLA-G e alla sua implicazione 
nella gravidanza e nell’impianto embrionale. 
Metodi e Risultati 
L’analisi dei livelli di HLA-G solubile (sHLA-G) in colture di cellule mononucleate 
da sangue periferico (PBMCs), derivate da soggetti sani ed attivate con 
lipopolisaccaride (LPS), ha evidenziato l’assenza di differenze tra i tre genotipi  
HLA-G 14 bp (+14/+14 bp, -14/+14 bp, +14/+14 bp), mentre sono state osservate 
concentrazioni piú elevate di interleuchina (IL)-10, il maggiore stimolatore della 
produzione di HLA-G, nelle colture PBMC-LPS-attivate con genotipo +14/+14 bp 
[2]. I nostri dati supportano l’ipotesi di un meccanismo feed-back loop tra le 
molecole HLA-G ed IL-10, che sostiene la loro produzione. I campioni -14/-14 bp e -
14/+14 bp con un genotipo -477 G/G polimorfismo a singolo nucleotide (SNP) nella 
regione regolatoria 5’ upstream (5’URR) del gene HLA-G, hanno presentato 
concentrazioni piú elevate di IL-10 nelle colture PBMC-LPS-attivate. Queste 
osservazioni potrebbero indicare come il –477 SNP possa avere un effetto 
indipendente sulle concentrazioni di IL-10 e le differenze non siano solo causate da 
linkage disequilibrium tra il polimorfismo G -477 SNP ed il polimorfismo -14 bp 
3’UTR. Infatti il polimorfismo -477 SNP é localizzato in vicinanza di un putativo 
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heat shock element (HSE) e potrebbe influenzare il legame del heat shock factor 1 
(HSF1) portando a differenze nell’espressione di IL-10 e sHLA-G. 
I livelli di sHLA-G sono aumentati nel plasma di donne gravide durante il primo 
trimestre rispetto a donne non gravide. Al contrario i livelli di sHLA-G nel plasma 
diminuiscono durante il terzo trimestre mentre subiscono un incremento al parto [3]. 
Abbiamo analizzato i livelli di sHLA-G e IL-10 nel plasma di 43 donne (15 non-
allergiche, 28 allergiche) durante il terzo trimestre, al parto e due anni dopo la 
gravidanza. E’ stato documentato un incremento significativo nei livelli di sHLA-G e 
IL-10 al parto indipendentemente dallo stato allergico, anche se le donne allergiche 
hanno presentato livelli di sHLA-G piú bassi rispetto alle donne non-allergiche. I 
livelli ridotti di sHLA-G non sono stati causati da una ridotta produzione di IL-10, in 
quanto sia le donne allergiche che quelle non-allergiche hanno mostrato livelli simili 
in tutti e tre i punti analizzati . Questo indica la presenza di altri fattori implicati nella 
produzione e/o regolazione di sHLA-G che differiscono tra i due gruppi. E’ possibile 
che il microambiente  citochinico Th2 presente negli individui allergici influenzi in 
modo diverso la secrezione di sHLA-G. I due gruppi hanno presentato livelli uguali 
due anni dopo la gravidanza, come se le donne allergiche avessero subito 
un’attivazione durante la gravidanza, ancora visibile dopo due anni, suggerendo la 
presenza di cambiamenti immunologici. I nostri dati hanno dimostrato che le 
molecole sHLA-G1 sono l’isoforma piú frequente nel plasma (75-80%) sia delle 
donne allergiche che non-allergiche durante il parto. Considerando la derivazione 
delle molecole sHLA-G1 da taglio proteolitico degli antigeni di membrana 
dipendente da  metalloproteinasi (MMP), puó essere ipotizzato che sHLA-G1 derivi 
dalla distruzione della placenta durante il parto,  evento caratterizzato da un 
incremento di MMP-9.  
Diversi dati hanno suggerito un ruolo importante per le molecole HLA-G nella 
sopravvivenza degli embrioni umani. L’espressione di HLA-G è stata documentata 
non solo a livello dei trofoblasti ma anche negli embrioni umani preimpianto. 
Jurisicova et al. [4] hanno evidenziato la presenza di mRNA HLA-G specifico in 
circa il 40% dei 148 embrioni testati. Inoltre gli autori hanno rilevato molecole HLA-
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G negli embrioni allo stadio di due cellule ed un incremento della velocità di 
clivaggio embrionale rispetto agli embrioni senza trascritto HLA-G. Questi dati 
propongono un’espressione variabile di HLA-G durante il periodo di sviluppo 
embrionale preimpianto. Al fine di avere un sistema in vitro e non invasivo per 
analizzare la secrezione di sHLA-G da parte dell’embrione, é stato utilizzato il 
protocollo di fertilizzazione in vitro, in cui gli oociti vengono fecondati in vitro e gli 
embrioni trasferiti 2-3 giorni dopo la fertilizzazione. Questo sistema ha permesso di 
valutare i sopranatanti di colture embrionali per la presenza di sHLA-G utilizzando 
un’analisi immunoenzimatica specifica. Nel 2002 è stata presentata la prima 
conferma in vitro del ruolo delle molecole HLA-G nell’impianto embrionale [5]. E’ 
stata analizzata la presenza di molecole sHLA-G in 285 sopranatanti di colture 
contenenti da uno a quattro embrioni ottenuti con ART. Nonostante non siano state 
osservate differenze cliniche, solo le donne con molecole sHLA-G nei sopranatanti 
delle colture embrionali hanno presentato impianto embrionale positivo (p= 2.56×10–
3
, Fisher’s exact p test). Questa è stata la prima osservazione effettuata nell’uomo che 
provi l’importanza dell’espressione di HLA-G nell’impianto embrionale.  
Nel 2004 è stata condotta l’analisi delle molecole sHLA-G in 318 sopranatanti da 
colture singole embrionali [6]. Abbiamo confermato la relazione significativa tra la 
secrezione di queste molecole da parte dell’embrione ed un’incrementata probabilità 
di impianto (p= 0.045, Mann-Whitney U test). Questi dati propongono l’analisi di 
sHLA-G nei sopranatanti embrionali come marcatore, unitamente alla 
caratterizzazione morfologica, per la selezione degli embrioni da trasferire. Dal 2002 
ad oggi sono stati analizzati più di sei mila sopranatanti di colture embrionali singole 
ottenute da procedure ART per la presenza di sHLA-G. Le discrepanze nei protocoli 
di coltura degli embrioni e nei sistemi di analisi di sHLA-G non hanno ancora 
confermato l’importanza di sHLA-G come marcatore di qualità embrionale e 
numerosi studi saranno necessari per standardizzare le procedure e confermare i 
risultati ottenuti [7,8]. 
Non è stata ancora spiegata l’assenza di molecole sHLA-G in una percentuale di 
embrioni ottenuti con ART. E’ possible ipotizzare la presenza di difetti germinali o 
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una produzione diminuita di IL-10. E’ stata analizzata la presenza di sHLA-G nei 
sopranatanti di colture di singolo embrione di coppie ammesse ad un secondo ciclo di 
fertilizzazione; queste coppie non avevano presentato colture embrionali positive per 
sHLA-G nel primo ciclo (0/31). I risultati ottenuti nel secondo ciclo ART hanno 
mostrato alcuni sopranatanti embrionali positivi per sHLA-G (14/40), suggerendo 
che la precedente mancanza di antigene fosse indipendente da difetti germinali. Sono 
stati analizzati i livelli di IL-10 nelle stesse colture embrionali. Non è stata osservata 
alcuna associazione tra la presenza di IL-10, la produzione ed i livelli di sHLA-G ed 
il risultato della gravidanza. Questi dati indicano come la mancanza di produzione 
sHLA-G in alcuni sopranatanti embrionali non sia dovuta a difetti germinali o 
diminuita produzione di IL-10  e suggeriscono la presenza di un programma 
gestazionale nella secrezione di sHLA-G. 
Numerosi problemi etici e legislativi stanno aumentando la necessità di ridurre il 
numero di oociti fertilizzati. Attualmente, la selezione degli oociti è svolta 
utilizzando caratteristiche morfologiche intra ed extracitoplasmatiche, senza avere 
una chiara associazione tra la morfologia e l’esito dell’impianto. La capacità 
dell’oocita di maturare, di essere fertilizzato e di svilupparsi in un embrione vitale 
inizia con la crescita oocitaria durante le prime fasi dello sviluppo follicolare e 
continua fino alla “capacitazione oocitaria” che sembra associarsi alla riserva di 
RNA messaggeri e proteine che supporterebbero le prime fasi di sviluppo 
embrionale, prima della completa attivazione del genoma embrionale. E’ noto come 
nelle prime fasi di sviluppo degli oociti fertilizzati la trascrizione sia silenziata e 
l’attivazione del genoma embrionale inizi allo stadio di 4-8 cellule, 
approssimativamente 70 ore dopo la fertilizzazione. Il fluido follicolare (FF) 
rappresenta il microambiente specifico per la maturazione oocitaria ed è stata 
proposta una possible relazione tra i componenti del FF e l’esito del ART.  Sono stati 
analizzati 50 FF per la presenza di molecole sHLA-G [9] e le molecole sHLA-G 
sono state rilevate nel 31.2% dei FF. Per valutare il possibile ruolo funzionale degli 
antigeni sHLA-G nei FF, abbiamo correlato i livelli di sHLA-G nei FF con le 
concentrazioni rilevate nei corrispondenti embrioni allo stadio di 4-8 cellule. Questa 
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analisi ha mostrato una relazione significativa tra la presenza di sHLA-G nei FF e nei 
corrispondenti sopranatanti di colture embrionali (p= 1.3x10-6; Fisher exact p test). 
Questi risultati potrebbero suggerire l’analisi di sHLA-G nei FF come metodica 
affidabile e non invasive per la selezione degli oociti, al fine di ottenere embrioni con 
un’elevata capacità di modulare l’espressione di HLA-G e conseguentemente con 
una maggiore probabilità di impianto. Abbiamo identificato le cellule della granulosa 
e la popolazione polimorfonucleata come produttori di  sHLA-G ma no abbiamo 
potuto caratterizzare gli oociti per problemi etici. 
Al fine di confermare il coinvolgimento di sHLA-G nella maturazione oocitaria, 
sono stati analizzati 152 oociti maturati in vitro, i cui sopranatanti possono essere 
caratterizzati facilmente per la presenza di sHLA-G senza subire l’influenza del 
microambiente materno. I nostri risultati hanno dimostrato come il complesso oocita-
cumulo (COC), caratterizzato dalle cellule della granulosa strettamente associate e 
dall’oocita, producano sHLA-G. La presenza di sHLA-G è stata rilevata nel 19% dei 
sopranatanti di colture di COC maturi. Al contrario non sono state rilevate molecole 
sHLA-G nei sopranatanti di colture di COC immaturi (p= 8.4 x 10-5; Fisher exact p 
test). Questi risultati mostrano, per la prima volta, la capacità dei COC maturi di 
produrre sHLA-G che potrebbe essere un marcatore di maturazione oocitaria.  
 
Conclusioni 
Le prospettive della ricerca relativa a HLA-G e gravidanza potrebbero riguardare la 
valutazione della possibile correlazione tra la produzione di sHLA-G da parte del 
COC e dell’embrione corrispondente e confermare il valore di sHLA-G come 
marcatore di competenza oocitaria/embrionale. La ricerca deve migliorare e 
standardizzare la rilevazione di sHLA-G al fine di ottenere risultati comparabili 
prima dell’utilizzo di HLA-G come marcatore per la selezione oocitaria/embrionale.  
Le molecole sHLA-G sono una delle risposte della ricerca alla necessità di una base 
razione per la selezione di pochi o possibilmente un singolo oocita/embrione 
competente, mantenendo ottimale la percentuale di successi del ART.  Il futuro del 
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ART sarà di combinare valutazioni morfologiche con l’analisi biochimica di 
molecole marcatori di competenza oocitaria/embrionale.   
L’identificazione di nuovi marcatori di competenza e vitalità oocitaria/embrionale 
potrá migliorare la potenzialità di queste metodologie non-invasive con implicazioni 
nella ricerca e nella clinica.   Sono stati analizzati i sopranatanti di colture di 39 COC 
immaturi, di 73 COC maturi e dei corrispondenti embrioni preimpianto per la 
presenza di proteine coinvolte nell’infiammazione, includendo citochine, 
chemochine (IL-1β, IL-1rα, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 
(P70), IL-13, IL-15, IL-17, Basic FGF, Eotaxin, G-CSF, GM-CSF, IFN-γ, IP-10, 
MCP-1 (MCAF), MIP-1α, MIP-1β, PDGF-BB, RANTES, TNF-α, VEGF) e la 
molecola solubile intercellular adhesion molecule 1 (sICAM-1) [12]. Le uniche 
proteine rilevate nei sopranatanti sono state sICAM-1 e IL-1rα, con sICAM-1 
espressa a livelli più elevati. Il rilascio di sICAM-1 è molto elevato nei COC 
immaturi, diminuiscenei COC maturi (p < 0.0001, Student t Test) e raggiunge valori 
ancora inferiori negli embrioni preimpianto (p < 0.0001, Student t Test). Non sono 
state osservate differenze significative tra i livelli di sICAM-1 tra COC immaturi con 
caratteristiche morfologiche diverse. Al contrario, i COC maturi con alto grado 
hanno presentato i livelli di sICAM più bassi. sICAM-1 sembra avere una chiara 
tendenza a diminuire dal COC immaturo a quello maturo sino all’embrione e 
potrebbe essere un marcatore biochimico di maturazione e grado del COC.  
La prospettiva per i laboratori di ART potrebbe essere l’utilizzo di parametri 
morfologici e di marcatori biochimici non invasivi per la selezione di oociti ed 
embrioni, riducendo il rischio di gravidanze multiple ed aumentando la probabilità di 
gravidanza. 
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ABSTRACT 
Problem  
HLA-G antigen maintains a tolerogenic condition at the feto-maternal interface, 
counteracts inflammation in autoimmune diseases and soluble HLA-G (sHLA-G) 
levels decrease in allergic-asthmatics. Taking into consideration these findings we 
analyzed if sHLA-G and IL-10 could be influenced by pregnancy and labour in 
allergic and non-allergic women.  
Method of Study 
sHLA-G isoforms and interleukin 10 (IL-10) levels were determined in the plasma 
samples of 43 women (15 non-allergic, 28 allergic) during third trimester, at delivery 
and 2 years after pregnancy by immunoenzymatic assays. 
Results 
A significant increase in sHLA-G and IL-10 levels was documented at delivery in 
both allergic and non-allergic women. Allergic women showed lower sHLA-G 
concentrations. sHLA-G1 was evidenced as the predominant plasma isoform.   
Conclusions 
The data propose an impressive boost in sHLA-G and IL-10 concentrations at 
delivery, regardless of the allergic status. The sHLA-G1 isoform is the main 
responsible for the increased sHLA-G levels at delivery. 
 
Key words: delivery, HLA-G5, plasma, sHLA-G1 
 
 
INTRODUCTION 
In the last years it has been demonstrated that HLA-G antigens are likely to play a 
pivotal role during pregnancy1, 2. The HLA-G antigens are currently defined as non-
classical MHC Ib antigens characterized by low allelic polymorphism and restricted 
tissue distribution. Furthermore, the presence of alternative mRNA splicing can 
generate different membrane-bound (HLA-G1, -G2, -G3, -G4) and soluble isoforms 
(HLA-G5, -G6, -G7)3. The expression of HLA-G molecules was first described in 
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extravillous cytotrophoblast cells, and it was further associated with the development 
and maintenance of a tolerogenic condition against the semiallogenic fetus4. Later, 
HLA-G expression has also been identified in adult thymic medulla, cornea, nail 
matrix, immature erythroid cells and pancreas5. Several reports have confirmed the 
possibility of membrane and soluble HLA-G molecules (sHLA-G) in the protection 
of the fetus from the deleterious effects of maternal immune cells. HLA-G molecules 
are able to induce apoptosis in CD8+ T cells via a Fas-FasL-dependent mechanism6,7, 
to inhibit natural killer cell activity8 and allo-specific CD4+ T cell proliferation9, to 
enhance regulatory CD4+ T cells10 and to inhibit the differentiation of dendritic 
cells11. Overall, these effects propose HLA-G molecules as efficient mediators of 
immunosuppressive functions against innate and adaptive immune responses.  
HLA-G expression itself is also regulated by the immune system. For example, 
interleukin 10 (IL-10) up-regulates HLA-G surface expression on decidual stromal 
cells, while it is down-regulated by IL-212.  
sHLA-G concentrations in serum/plasma of pregnant women have been associated to 
clinical outcome1. sHLA-G levels in plasma from women who subsequently develop 
preeclampsia are lower than control patients, as early as in the first trimester13. In 
comparison to non-pregnant women, sHLA-G levels strongly increase during the 
first trimester. Interestingly, women with significantly decreased sHLA-G levels in 
the second trimester have an increased risk of developing preeclampsia and/or 
intrauterine growth retardation (IUGR)13.  
Pregnancy is further associated with alterations in cytokine levels. We have 
previously demonstrated an increase of spontaneous IL-10 production during 
pregnancy compared to two years after pregnancy14. IL-10 is one of the main 
enhancers of HLA-G production, with a clear feed-back loop interaction between 
these two molecules15. 
We have further demonstrated the relationship between sHLA-G and IL-10 in a 
study where we described a clear decrease of sHLA-G and IL-10 levels in asthmatic 
patients16. This indicates that sHLA-G levels could be affected in conditions where 
there is an altered cytokine balance. 
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The aim of this study was to analyze possible differences in sHLA-G production in 
allergic and non-allergic pregnant women. We analyzed the levels of soluble HLA-
G, the two isoforms sHLA-G1 and sHLA-G5, as well as IL-10 in plasma from 43 
women (28 allergic and 15 non-allergic) at two time-points during pregnancy (third 
trimester, delivery) as well as 2 years after pregnancy. 
 
  
MATERIALS AND METHODS 
Study subjects and diagnosis of allergy 
Plasma samples were randomly selected from women participating in a larger 
prospective study on allergic heredity including 281 infants and their parents, 
described in detail elsewhere15. The women were classified as allergic (n = 28) or 
non-allergic (n = 15) (Table I) based on their clinical history (allergic bronchial 
asthma and/or allergic rhinoconjunctivitis to animal dander and/or to pollen) together 
with skin prick test (SPT) results. The same nurse performed SPT according to the 
manufacturer’s recommendation (ALK, Copenhagen, Denmark) against the 
following inhalant allergens: birch, timothy, mugwort, horse, rabbit cat, dog, and 
Dermatophagoides farinae (Soluprick 10 Histamine Equivalent Prick). Histamine 
chloride (10mg/mL) served as the positive control and the allergen diluent as the 
negative control. The SPT has been considered positive if the weal diameter after 
15min was ≥ 3mm.  
Demographic data are shown in Table I. All pregnancies were term 
pregnancies (> 37 weeks) and all infants had birth weights within the normal range. 
There were no statistically significant differences regarding maternal age, mode of 
delivery, sex of child, or the number of children between the two groups. The 
clinician (CN) who met all families both before and after the delivery recorded that 
the women unwillingly used inhalation steroids, antihistamines or other drugs. None 
of the women used systemic steroids. Approval from the Human Ethics Committee at 
Huddinge University Hospital, Stockholm, Sweden has been granted. All families 
have given their informed consent to the study. 
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Samples 
Plasma samples were obtained from peripheral blood samples collected from 
the same women at 3 time points; during the 3rd trimester of pregnancy, at delivery 
and at a non-pregnant state 2 years post-partum. All of the samples were stored at -
20oC until analysis.. The samples were thawed prior to the ELISA assay and freezing 
and thawing of the samples was avoided. 
Cytometric Bead Array  
Levels of IL-10 in plasma were measured using the Cytometric Bead Array 
(CBA, BD Biosciences Pharmingen, San Diego, CA, USA) technique according to 
the recommendations from the manufacturer. Briefly, the standards and samples 
were diluted in assay diluent mixed with the PE-labeled beads and incubated for 3 h. 
After incubation the samples and standards were washed to remove unbound material 
and analyzed using the BD CBA software (BD Biosciences Pharmingen, San Diego, 
CA, USA). Calibration of the flow cytometer was been performed by using BD 
FACSComp™ (BD Biosciences Pharmingen, San Diego, CA, USA) and BD 
CaliBRITE™ Beads (BD Biosciences Pharmingen, San Diego, CA, USA). The assay 
sensitivity was 3.3 pg/ml.  
 
Measurement of total sHLA-G levels by enzyme-immunosorbent assay (ELISA) 
Total sHLA-G (sHLA-G1 and HLA-G5) antigen concentrations were 
investigated by enzyme immunosorbent assay, as reported in the Essen Workshop on 
sHLA-G quantification18. Briefly, 20 µg/ml MEM-G9 MoAb (Exbio, Praha, Czech 
Republic) were used as capture antibody and anti-beta 2 microglobulin – HRP 
conjugated MoAb, (Dako, DK) as detection antibody. The concentration of sHLA-G 
was estimated as a mean of triplicate plasma samples by absorbance at 450 nm on a 
microplate reader (Wallac Victor 3, PerkinElmer, Waltham, Massachusetts, USA). 
HeLa cell wild type culture supernatants were used as negative controls and 
transfected HeLa-G5 cells (kindly provided by Prof. E.Weiss, Institut fur 
Anthropologie und Genetik, LMU, Munchen, Germany) as positive controls. Culture 
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supernatants were collected at 90% cell confluence and concentrated by the 
lyophilization procedure. Following depletion of albumin by the Albumin depletion 
kit (Enchant Life Science kit, Pall Corporation, MI, US), purification of the sHLA-G 
proteins was carried out as previously reported19. The sHLA-G molecules obtained 
were used as standards at different dilutions (30, 25, 20, 15, 6, 3, 1.5, 1 ng/ml). The 
standard curve is shown in Figure 1A. The intra-assay coefficient of variation (CV) 
is 1.4%, the inter-assay CV was 4.0%. The limit of sensitivity was 1.0 ng/ml.  
 
Measurement of HLA-G5 levels by enzyme-immunosorbent assay (ELISA) 
Plasma sample concentrations of HLA-G5 were quantified following the 
protocol proposed by Rebmann et al.18. Briefly, 20 µg/ml 5A6G7 MoAb (Exbio, 
Praha, Czech Republic) were used as capture antibody and biotinylated anti-HLA 
class I W6/32 MoAb, (Dako, DK) and extravidin-peroxidase (Sigma-Aldrich, Italy) 
was used for detection. The concentration of sHLA-G was estimated as a mean of 
triplicate plasma samples by absorbance at 450 nm on a microplate reader (Wallac 
Victor 3, PerkinElmer, Waltham, Massachusetts, USA).  We used the same standards 
as the total sHLA-G ELISA. The standard curve is shown in Figure 1B.  The intra-
assay coefficient of variation (CV) was 2.0%, the inter-assay CV was 3.5%. The 
limit of sensitivity was 1.0 ng/ml.  
 
Determination for non classical sHLA-G1 
After ELISA measurements of plasma levels of total sHLA-G and HLA-G5, 
the amount of sHLA-G1 was expressed as the difference between total sHLA-G 
(sHLA-G1 and HLA-G5) and HLA-G5 concentrations.  
 
Statistical analysis 
Statistical analyses were performed with STATISTICA 7.1 software (Statsoft 
Inc., Tulsa, OK, USA), by the Division of Mathematics at Stockholm University (Dr. 
Jan-Olov Persson). To analyse HLA-G variation over time, Friedman’s test was used 
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and the influence of background variables was measured by logistic regression. 
Fishers’s exact test was used to test for differences in the proportion of HLA-G 
positive individuals between the two groups. For all results the Mann-Whitney U test 
was used to test for differences of median values between groups. Correlations 
between HLA-G levels and IL-6 and IL-10 respectively, was analysed with 
Spearman rank test. A difference was considered significant if p<0.05.  
 
 
RESULTS 
Labour influences sHLA-G and IL-10 plasma levels 
To evaluate the effect of pregnancy and labour on the plasma sHLA-G levels, 
we measured sHLA-G in a total of 43 women (15 non-allergic and 28 allergic) at 
three occasions, during the 3rd trimester, at labour and at 2 years post partum. Soluble 
HLA-G plasma levels were significantly increased during labour in comparison to 
the third trimester and two years after delivery (Fig 2A). The IL-10 plasma levels 
followed the same pattern (Fig 2B).  
The Spearman correlation coefficient between sHLA-G and IL-10 plasma 
levels was calculated for all the individuals at the different time points, but no 
significant correlations between these factors were observed.  
 
Allergy is associated with reduced sHLA-G plasma levels during pregnancy and 
at delivery 
When subdividing the women according to allergic status, plasma levels of 
both sHLA-G (Fig 3A) and IL-10 (Fig 3B) presented the same behaviour towards 
labour. In both groups of women, sHLA-G (non allergic, p<0.001; allergic: p<0.001, 
Friedman test) and IL-10 (non-allergic, p<0.05; allergic, p<0.01, Friedman test) 
levels were elevated at delivery in comparison to the third trimester and two years 
after delivery. Comparing non-allergic and allergic women at each time point, 
showed that there was a significant difference in the proportion of sHLA-G positive 
samples between allergic (11/28) and non-allergic women (14/15) during the 3rd 
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trimester (p=0.0009, Fisher exact test) with lower HLA-G levels in allergic women 
(p<0.01; Mann Whitney U test). Also, allergic women had lower sHLA-G levels 
(38.0 ng/ml) than non-allergic women (62.0 ng/ml) at delivery (Fig 3A) (p<0.05, 
Mann Whitney U test). Interestingly, no significant differences were evidenced 2 
years after pregnancy (p=NS; Mann Whitney U test). These differences between 
sHLA-G levels in allergic and non-allergic women remained after control for 
background variables in both third trimester (p=0.006, Logistic regression) and 
delivery (p=0.007, Logistic regression). 
IL-10 levels increased at delivery in both allergic and non-allergic women, but 
no significant differences were found between the two groups (Fig 3B). 
 
sHLA-G isoform analysis 
The analysis of sHLA-G isoforms (sHLA-G1, HLA-G5) demonstrated that 
sHLA-G1 was the predominant isoform responsible for the increase of sHLA-G 
levels in plasma during delivery (Fig 4A, B). 
Subdividing the women accordingly to the allergic status revealed that sHLA-
G1 increased at delivery both in allergic (from 0 ng/ml in the 3rd trimester to 36.0 
ng/ml at delivery) and non-allergic (from 22.0 ng/ml in the 3rd trimester to 42.2 
ng/ml at delivery) women (Fig 4A), with a clear increase during labour in 
comparison to the third trimester and two years after delivery (non-allergic, 
p<0.0001; allergic, p<0.0001, Friedman test) and higher levels in non-allergic 
women both in the third trimester (p= 0.001; Mann Whitney U test) and at the 
delivery (p<0.05; Mann Whitney U test). Moreover there was a significant difference 
in the proportion of sHLA-G1 positive samples between allergic (10/28) and non-
allergic (14/15) women during the third trimester (p=0.0003, Fisher exact test).  
HLA-G5 levels presented the same concentrations in atopic and non-atopic 
women at all the three time-points (Fig 4B), with no differences between time points 
(non-allergic, p=NS; allergic, p=NS, Friedman test).  
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DISCUSSION 
We focused our study on the comparison of sHLA-G plasma concentrations at 
third trimester, delivery and two years after pregnancy in allergic and non-allergic 
women. The results demonstrated an impressive increase of sHLA-G molecules at 
delivery in both allergic and non-allergic women. Furthermore, our data revealed 
significantly reduced levels of sHLA-G molecules at delivery in allergic women in 
comparison to non-allergic women. A similar pattern was observed for plasma IL-10, 
with increased levels at delivery, but without any difference between allergic and 
non-allergic women. Plasma levels of IL-6 also increased at delivery, indicating a 
process of labour at the delivery time point. Our results demonstrate that the delivery 
process is able to affect both sHLA-G in plasma and systemic cytokine levels in both 
allergic and non-allergic women,  
Interestingly, sHLA-G levels were lower in allergic women than in non-allergic 
women at delivery. The reduced sHLA-G levels were not caused by deficient IL-10 
production, as allergic and non-allergic women presented equal amounts at all three 
time points investigated. This indicates that other factors involved in sHLA-G 
production and/or regulation differ between these two groups of women. It is 
possible that the Th2 cytokine microenvironment present in an allergic individual20 
differently influences the sHLA-G secretion. Of course to definitely prove that 
allergic status affects the sHLA-G production, it would have been necessary to 
evaluate these women also prior to pregnancy. As the women were enrolled in the 
study when visiting the maternity ward, this was not feasible. 
Reduced sHLA-G levels have been described in pregnancies complicated by 
preeclampsia and intra-uterine growth retardation21, 22. HLA-G molecules have been 
implicated in the regulation of uterine natural killer (uNK) cells. The uNK cells are 
supposed to participate in the process of placentation and being particularly 
important for the process of uterine spiral artery transformation. A dysregulation of 
uterine NK cells has been suggested in pregnancy-associated pathological conditions 
like preeclampsia (PE); and modified HLA-G expression on trophoblasts and/or 
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altered levels of sHLA-G have been implicated as possible mechanisms for this 
dysregulation. Soluble HLA-G may contribute locally and further away from the 
invading trophoblast to trigger functional maturation of the uNK cells and thereby 
contribute to vascular remodelling and decidualization. Soluble HLA-G levels in 
plasma from women who subsequently developed PE were lower than control 
patients, as early as the first trimester23. The reduced release of sHLA-G into the 
maternal circulation in preeclampsia may alter the maternal-fetal immune 
relationship and thus be involved in the cause of this disorder.  
However, the absence of any complication in allergic women and their babies 
suggests a non-significant clinical influence of the observed differences in sHLA-G 
plasma levels in comparison to non-allergic women. It is interesting in relation to the 
old Th1/Th2 pregnancy dogma24, suggesting that allergic women with their Th2 
profile would have higher parity compared to non-allergic women. This is highly 
questionable, but the supposed Th2 profile of allergic women could perhaps 
compensate for the lower sHLA-G levels. 
Non-allergic women have higher sHLA-G plasma levels at delivery, while two 
years after pregnancy, the two groups presented equal levels. Allergic women seem 
to experience a prime during pregnancy that is still evident two years after 
pregnancy. These data are in agreement with our recent study that demonstrated the 
presence of immunological changes imposed by pregnancy still evident two years 
after labour16.   
        The difference in the levels of sHLA-G between allergic and non-allergic 
women could be also genetically determined. The HLA-G gene is characterized by a 
polymorphism of deletion/insertion of 14 base pairs at the 3’ untranslated region of 
the exon 8 25. This polymorphism influences the stability of the HLA-G mRNA and 
in particular the presence of the 14bp sequence destabilizes the mRNA and 
consequently reduces the protein production17, 26. This insertion/deletion 
polymorphism is in linkage disequilibrium with particular alleles in the classical 
HLA loci including HLA-DR327. Some allergic disorders may be associated with 
polymorphisms in the HLA region that may be in linkage disequilibrium with this 
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polymorphism predisposing to low sHLAG levels. Moreover the HLA-G protein 
production seems to be controlled also by HLA-G gene polymorphisms at the 5’ 
upstream regulatory region28, mutations29 and microRNAs30. It would be interesting 
to evaluate all these mechanisms in the attempt to explain the different HLA-G 
production by allergic and non-allergic women.   
To better investigate the nature of sHLA-G increase we analyzed the sHLA-G1 
and HLA-G5 isoforms, which represent the main components of the total sHLA-G 
plasma amount. Our data demonstrated that sHLA-G1 molecules were the most 
frequent isoform in plasma (75-80%) in both allergic and non-allergic women during 
labour. As sHLA-G1 molecules are considered mainly originated by 
metalloproteinase (MMP)-dependent shedding at post-translational level of the 
membrane antigens31, it could be hypothesized that sHLA-G1 could derive from the 
placenta disruption during the labour that is characterized by an increase in MMP-9 
amounts32.  
On the opposite, the production of HLA-G5 soluble isoform is mainly ascribed 
to splicing mechanisms at gene levels that occur in the IL-10 activated CD14+ 
peripheral blood monocyte population. IL-10 represents the main activator of CD14+ 
cells, and it is well accepted that HLA-G5 production mediated by IL-10 represents a 
mechanism to counteract inflammation. In our study we have observed a significant 
increase of plasma IL-10 levels at delivery, without any significant difference 
between allergic and non-allergic women. The increased levels of IL-10 at delivery 
could affect the HLA-G5 production, associated to an anti-inflammatory response 
that tries to counteract the inflammatory status of delivery33.. 
In summary our results demonstrate an increase of sHLA-G plasma 
concentrations at delivery compared to the 3rd trimester and 2 years after delivery. 
sHLA-G plasma levels in allergic women followed the same pattern as in non-
allergic women with the highest levels at delivery. However, at delivery, sHLA-G 
levels were lower in allergic women than in non-allergic women. The reduced 
sHLA-G levels were not caused by deficient IL-10 production, as allergic and non-
allergic women produced equal amounts at all three time points investigated. Further 
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experiments are needed to understand the mechanisms responsible for the reduced 
production of sHLA-G in allergic women, that in this study however, did not 
represent a significant hazard for a normal delivery. 
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Table I. 
Demographic data of allergic and non-allergic women 
 
 Allergic women 
(n=28) 
Non-Allergic women 
(n=15) 
p value° 
Maternal age at 
delivery (years) 
32 
24 - 44 
32 
27 - 40 
0.2975 
Gestation length 
(months) 
40 
37 - 42 
40 
38 - 43 
0.5770 
Mode of delivery *ECS: 4/28 
VD: 24/28 
ECS: 2/15 
VD: 13/15 
0.9323 
Sex of child Girl: 14/28 
Boy: 14/28 
Girl: 10/15 
Boy: 5/15 
0.2999 
Number of children 1 
1 - 4 
2 
1 - 3 
0.6427 
 
 
*ECS: elective caesarean section; VD: vaginal delivery 
° Mann Whitney sum of rank test 
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Legends to figure 
Figure 1. Standard curve of the ELISA assays for total sHLA-G (A) and HLA-G5 
isoform (B). The standard sHLA-G was used at different dilution (30, 25, 20, 15, 6, 
3, 1.5, 1 ng/ml) in triplicate. The enzyme-linked immunosorbent assays were 
performed as described in the Material and Methods section. The detection limit, 
3.29 SD added to the mean optical density of repeated negative control 
measurements, is reported (Dotted line). The bold line indicates the linear regression 
and the dashed lines the 95% confidence interval. 
  
Figure 2. Molecule levels in plasma samples from 43 pregnant women (allergic and 
non-allergic) at the third trimester (3rd), delivery (del) and 2 years after delivery (2ys) 
measured by enzyme-linked immunosorbent assay. (A) sHLA-G; (B) IL-10. * 
Difference between time points (Friedman test); ° Mann Whitney U test, was used to 
test for differences of median values between groups. 
 
Figure 3. Soluble HLA-G (A) and IL-10 (B) levels in plasma samples from 15 non-
allergic (grey) and 28 allergic (white) women at the third trimester (3rd), delivery 
(del)  and 2 years after delivery (2ys) measured by enzyme-linked immunosorbent 
assay. * Difference between time points (Friedman test); ° Mann Whitney U test, 
was used to test for differences of median values between groups. 
 
Figure 4. Soluble HLA-G1 (A) and HLA-G5 (B) isoform levels in plasma samples 
from 15 non-allergic (grey) and 28 allergic (white) women at the third trimester (3rd), 
delivery and 2 years after delivery (2ys)  measured by enzyme-linked 
immunosorbent assay. * Difference between time points (Friedman test); ° Mann 
Whitney U test, was used to test for differences of median values between groups. 
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ABSTRACT 
Oocyte selection  with the highest competency  represent a major goal  in IVF.  
Several studies have demonstrated that non classical HLA class I HLA-G molecule 
modulation creates a tolerogenic microenvironment at the feto-maternal interface and 
it seems to be implicated in embryo implantation. This study investigated if soluble 
HLA-G molecules production by the cumulus-oocyte complex (COC) could be a 
marker of oocyte maturation.  sHLA-G molecule levels were analyzed using Bio-
Rad’s Bio-Plex assay in 152 COC supernatants obtained from 42 women and 
maturated by an “in vitro maturation procedure”. The presence of sHLA-G 
molecules was confirmed by Western blot technique. The results demonstrate 
detectable amounts of sHLA-G molecule ranging from 300 to 800 pg/ml in 14/73 
(19%) COCs that generated mature oocytes and the complete absence of detectable 
sHLA-G antigens in the supernatants of COCs that corresponded to immature 
oocytes. 
The detection of sHLA-G molecules in the COC culture supernatants corresponding 
to matured oocytes is proposed as a possible marker to identify the gametes with a 
higher functionality. This non-invasive marker could be used in addition to 
morphological approaches to reduce the number of fertilized oocytes and transferred 
embryos.  
 
Key words: HLA-G; oocyte; in vitro maturation 
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1. INTRODUCTION 
Currently, several oocytes are fertilized during IVF procedures and two or more 
embryos are transferred to the uterus in order to increase the chance of a positive 
pregnancy. However, this approach results in a high number of multiple pregnancies, 
perinatal mortality and morbidity. The necessity to overcome these risks together 
with the presence of ethical problems has increased the interest in selecting the 
gametes with the highest competency. This point is of extreme interest in Italy, 
where the law 40/2004 states that no more than three embryos must be created at any 
one time and all the embryos created must be transferred together even if the couple 
does not need all the embryos (Fineschi et al., 2005).  
 In this context the identification of validated markers for oocyte selection represents 
a fundamental step in IVF.  
Several studies have demonstrated that HLA-G antigen modulation creates, by direct 
and indirect mechanisms, a tolerogenic microenvironment at the feto-maternal 
interface (Rouas-Freiss et al., 2007). HLA-G molecules inhibit, together with HLA-
C and HLA-E, the innate Natural Killer response against cytotrophoblast cells which 
lack classical HLA class I and II expression (Moffett et al., 2006; Khalil-Daher et al., 
1999; Rouas-Freiss et al., 1997;). HLA-G antigens affect the adaptative cellular 
response inducing the apoptosis of cytotoxic CD8+ T lymphocytes (Le Gal et al., 
1999; Fournel et al., 2000), impairing CD4+ T cell functions and preventing 
dendritic cell maturation (Bainbridge et al., 2000;  Lila et al., 2001). HLA-G 
molecules also induce immunosuppressive regulatory T cell development (Feger et 
al., 2007; Selmani et al., 2008).   
Detectable levels of soluble HLA-G (sHLA-G) molecules in a percentage of 
follicular fluids (FFs) from patients admitted to IVF procedures have recently been 
reported (Rizzo et al., 2007) and  granulosa cells have been identified as producers of 
sHLA-G molecules. The granulosa cells which surround the mammalian oocyte are 
known as the cumulus oophorus. These cells create a structural pathway for cell-to-
cell communication (Gilchrist et al., 2004) where cumulus cells provide several 
trophic or metabolic factors to the preovulatory oocyte (Elvin et al., 1999). Several 
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results indicate that the measurement of gene transcription levels in cumulus cells 
would reliably complement the morphological oocyte evaluation providing a useful 
tool for selecting oocytes with greater chances to be fertilized (Feuerstein et al., 
2007; Cillo et al., 2007).  
Considering the presence of sHLA-G in FFs during the oocyte maturation this study 
verified if it is a marker of this process. The culture supernatants of “in vitro 
matured” oocytes were analyzed for sHLA-G presence. The target of “in vitro 
maturation” (IVM) technique is to retrieve immature oocytes from the ovary and to 
induce their maturation in vitro. We have employed in vitro co-cultures of oocytes 
and cumulus cells to restore support from the surrounding cumulus cells to the oocyte 
(Combelles et al., 2002; Eppig, 1991).  This system has allowed us to analyze the 
sHLA-G production by the cumulus-oocyte complex (COC) without the influence of 
the in vivo maternal microenvironment.  
 
 
2. MATERIALS AND METHODS 
2.1 Patients     
The oocyte employed for this study have been obtained from regularly cycling 
patients attending the Biogenesi Reproductive Medicine Centre of Monza, Italy, for 
an Assisted Reproduction Technique with In Vitro Maturation Protocol (IVM).  
Couples included in the trial had an indication to IVF procedure because of infertility 
due to male factor, tubal factor, stage I/II endometriosis, polycystic ovarian 
syndrome (PCO) or unexplained cause. All the women included had regular cycles of 
26-35 days. A written informed consensus has been obtained from all participating 
couples. 
We have considered just one cycle per couple. After maturation process we have 
used from one to three oocytes according to the Italian Law 40 on IVF (Fineschi et 
al., 2005). Following these criteria, 42 women have been recruited for the study. 
Women characteristics are reported in Table 1. 
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Oocyte recovery has been performed by means of transvaginal ultrasonound–guided 
follicle aspiration, using a single lumen aspiration needle (Gynetics cod. 4551-E2 
Ø17- gauce 35 cm) connected to a vacuum pump (Craft Pump pressure 80-90 
mmHg). The aspirated follicular fluids, containing COCs, have been washed with 
prewarmed Flushing Medium with heparin (Medi-Cult product n. 10760125, 
Denmark). The oocytes have been detected under a stereomicroscope, examined and 
classified on the basis of their morphology. Oocytes with signs of mechanical 
damage or atresia have been discarded.  
Immature COCs have been individually cultured in a 4-well culture dish with 250µl 
ml of IVM Medium (vial 2 of IVM system medium; Medicult no. 82214010, 
Denmark) supplemented with rec–FSH 0,075 IU/ml (Serono, Italy), hCG 0,1 IU/ml 
(Serono, Italy) and 10% Serum Protein Substitute (SPS no.3010– Sage Media- USA) 
for 30 hrs. 
Following the maturation period, the supernatants have been collected from each 
culture system containing a single COC and stored at -20°C until being tested for the 
presence of sHLA-G. The oocytes have been denuded from cumulus and evaluated 
for the presence of the first polar body to confirm Metaphase II stage. The Metaphase 
II oocytes have been considered mature, while the Metaphase I, degenerated and 
germinal vescicle oocytes have been defined immature (Huang et al., 2002). The 
mature oocytes have been classified accordingly to surrounding cumulus cells as 
follow: Grade A: expanded cumulus with multilayer and slack cumulus cells with a 
full adhesion to the oocyte with cumulus; Grade B: full or spare compact cumulus 
with one to three layers of cumulus cells with a spare adhesion to the oocyte (Table 
2a); and graded on the first polar body and cytoplasm characteristics: Grade 1: 
homogenous cytoplasm and round polar body; Grade 2. oocyte with variations in 
colour or granularity of the cytoplasm and/or presence of inclusions, vacuoles or 
retractable bodies , but a round polar body; Grade 3. oocyte with variations in colour 
or granularity of the cytoplasm and/or presence of inclusions, vacuoles or retractable 
bodies with a fragmented polar body (Table 2b)). The subdivision of the mature 
oocytes is reported in Table 3.  
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2.2 sHLA-G  ELISA  
sHLA-G1, obtained from the proteolytic cleavage of the membrane bound HLA-G1, 
and HLA-G5, generated by mRNA alternative splicing, have been assayed as 
reported in Essen Workshop on sHLA-G quantification (Rebmann et al., 2005) using 
as capture antibody the MoAb MEM-G9 (Exbio, Praha, Czech Republic), which 
recognizes HLA-G molecule, in beta2-microglobulin-associated form, at the 
concentration of 20 µg/ml. The anti-beta2 microglobulin MoAb – HRP conjugated, 
(Dako, Glostrup, Denmark) has been used as detecting antibody diluted 1:1000 in 
PBS1x. HeLa cell wild type culture supernatants have been used as negative control, 
transfected HeLa-G5 cell (kindly provided by Prof. E.Weiss, Institut fur 
Anthropologie und Genetik, LMU, Munchen, Germany) as positive control. Culture 
supernatants have been collected at cell confluence and concentrated by 
lyophilization procedure. Following depletion of albumin by Albumin depletion kit 
(Enchant Life Science kit, Pall Corporation, MI, USA), the purification of the sHLA-
G proteins has been carried out as previously reported (Le Friec et al., 2003). The 
sHLA-G molecules obtained have been used as standard at different dilutions. The 
COC culture medium has been use for the standard dilution. 
The detection limit has been calculated with repeated measurements of a negative 
control obtained with the culture medium. In this way all the variables of the assay 
have been considered. We have calculated the mean of the optical density (OD) 
value obtained in the negative control wells, present in triplicate in each plate, and a 
standard deviation, with the value of lower limit of detection being 3.29 standard 
deviations (SD) added to the mean OD value (Anderson DJ, 1989). In this case, there 
is only a 5% chance of classifying a result in the wrong population and the lower 
limit of detection sample determinations are above this midway concentration with a 
probability of the 95%. The limit of sensitivity is 600 pg/ml. 
 
 135 
2.3 Bio-Plex system  
2.3.1 Covalent coupling of antibodies to microspheres. Covalent coupling of the 
anti-sHLAG antibodies to the carboxylated polystyrene microspheres (Bio-Rad, 
Hercules, CA, USA) has been performed using the Bio-Plex amine coupling kit (Bio-
Rad, Hercules, CA, USA).  Briefly, the microspheres' stock solution has been 
dispersed by bath sonication until a homogeneous distribution of the microspheres 
has been observed. For a 1x scale coupling reaction, 100 µl of monodisperse beads 
(1.25 × 106 microspheres), has been centrifugated at 14,000 x g for 4 min and 
washed with 100 µl of bead wash buffer. This bead pellet has been resuspended in 80 
µl of bead activation buffer, vortexed for 30 sec, and then sonicated by bath 
sonication for 30 sec. Solutions of N-hydroxysulfosuccinimide (S-NHS) and 1-ethyl-
3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) (Pierce 
Biotechnology, Rockford, USA), both at 50 mg/ml, have been prepared in bead 
activation buffer immediately prior to its use, and 10 µl of each solution has been 
sequentially added to stabilize the reaction and activate the microspheres. This 
suspension has been vortexed for 30 sec and then agitated with a rotator at room 
temperature for 20 min in the dark. Then activated beads have been washed twice 
with 150 µl of PBS, pH 7.4, incubated with 5 µg of MoAb MEM-G9 (Exbio, Praha, 
Czech Republic) in a final volume of 500 µl of PBS, pH 7.4 and agitated with a 
rotator at 4°C overnight in the dark. After washing with 500 µl of PBS, pH 7.4 the 
beads have been resuspended with 250 µl of blocking buffer and agitated at room 
temperature for 30 min in the dark. The coupled beads have been washed with 500 µl 
of storage buffer, resuspended in 150 µl of storage buffer and counted with a 
hemacytometer.  
Coupling efficiency of monoclonal antibodies has been tested by staining 10,000 
microspheres with biotinylated antibody directed to the source of the capture 
antibody (goat anti-mouse immunoglobulin G (e-Bioscience, San Diego, USA) 
followed by streptavidin-PE for 30 min and 10 min at room temperature in the dark 
respectively. The microspheres, resuspended in 150 µl of storage buffer, have been 
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measured and analyzed with the Bio-Plex system (Bio-Rad Laboratories, Hercules, 
CA, USA). 
 
2.3.2 s-HLAG Bio-plex assay. COC culture supernatants have been assayed for 
sHLA-G using a bead array system Bio-Plex (Bio-Rad, Hercules, CA, USA) 
according to the manufacturer's instructions. Briefly, 50 µl of sHLA-G standards 
(prepared in the same fresh culture medium and assayed in duplicate) or samples 
(COC culture supernatants in duplicate) have been incubated with 50 µl of anti-
sHLA-G conjugated beads (5000 beads/well) in 96-well filter plates for 60 min at 
room temperature with shaking. Plates have been washed by vacuum filtration three 
times with 100 µl of Bio-Plex wash buffer, 25 µl of biotinylated antibody W6/32 (10 
µg/ml) (Dako, Glostrup, Denmark) has been added, and plates were incubated for 30 
min at room temperature with shaking. After three filter washes, 50 µl of 
streptavidin-phycoerythrin has been added, and the plates have been incubated for 15 
min at room temperature with shaking. Finally, plates have been washed by vacuum 
filtration three times, beads have been suspended in 125 µl of Bio-Plex assay buffer, 
and samples have been analyzed on the Instrument Bio-Plex system in combination 
with the Bio-Plex Manager software. The standard curves for sHLA-G have been 
used from 24000 to 93,75 pg/ml and the minimum detectable dose was 300 pg/ml. 
The detection limit has been calculated with repeated measurements of a negative 
control obtained with the culture medium. In this way we have considered all the 
variables of the assay. We have calculated the mean of the fluorescence value 
obtained in the negative control wells, present in triplicate in each plate, and a 
standard deviation, with the value of lower limit of detection being 3.29 standard 
deviations (SD) added to the mean fluorescence (FI) value (Anderson DJ, 1989). In 
this case, there is only a 5% chance of classifying a result in the wrong population 
and the lower limit of detection sample determinations are above this midway 
concentration with a probability of the 95%. The specificity of this assay has been 
validated with an isotype control (Mouse IgG1 Isotype control, code 1B-457-C100 
biotin; Exbio, Praha, Czech Republic) used in the place of W6.32 biotin moAb. The 
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background observed was lower than the selected detection limit (data non shown). 
We have obtained the limit of sensitivity at 300 pg/ml. 
2.4 Western blotting 
The presence of HLA-G molecules in COC supernatants have been analysed by 
denaturating SDS-PAGE in a group of ELISA sHLA-G positive samples (Rizzo et 
al., 2007). Briefly, 100x concentrated and albumin depleted pooled COC 
supernatants have been loaded on 10% SDS- polyacrilamide gel, electrophoresed at 
80V for 2 hours and blotted onto PVDF membrane (Immobilon-P Millipore, 
Billerica, MA, USA) by electrotransfer at  100V  for 45 minutes in 25mM Tris 
Buffer, 190mM Glycine, 2% SDS and 20% (V/V) Methanol. Blocking has been 
carried out with 5% nonfat dry milk, Tris 100mM pH7.5, NaCl 150mM over night at 
4°C. After two washes, the membrane has been incubated with MEM-G1 moAb 
(Exbio, Praha, Czech Republic) (10µg/ml), which recognizes HLA-G molecule in 
denaturated form, for 3 hours at room temperature with gentle shaking. The sHLA-G 
molecules have been detected using Protein-G HRP (BioRad, Hercules, CA, USA) at 
dilution of 1:5000 in 10mM Tris pH8.0, 150mM NaCl, 0.1% Tween 20. Reactions 
have been developed by chemiluminescence with SuperSignal enhanced 
chemiluminescence kit (Super Signal West Pico system, Pierce, Rockford, IL, USA) 
and captured by Chemiluminescence Imaging Geliance 600 detection system 
(PerkinElmer, CT, USA). Soluble HLA-G molecules, purified as previously reported 
(sHLA-G ELISA Section), have been used as positive control, culture medium as 
negative control. The COC supernatants have been loaded at the same total protein 
concentration that has been evaluated by Quick Start Bradford protein assay (Bio-
Rad Laboratories, Hercules, CA, USA). The molecular weights have been 
determined with the BenchMark (Invitrogen, CA, US) pre-stained protein ladder 
(range 10-200 kD).   
2.5 Statistics 
The Fisher’s exact test has been used to analyze the different frequencies in sHLA-G 
positivities between COCs that generated mature or immature oocytes.  
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The Correlation Z test and the Regression test have been used to analyze the 
interpolation of ELISA and Bioplex standard curves.  
The statistical analysis have been conducted using Stat View software package (SAS 
Institute Inc, Cary, NC, USA). P-value of 0.05 is considered significant (two tailed).    
 
3. RESULTS 
3.1 Comparison between the sHLA-G ELISA and the sHLA-G Bioplex assays 
We have compared the Bio-Plex assay and ELISA technique in quantifying sHLA-G 
molecules. 
We have used the same capture antibody and standard regents in both the techniques 
in order to maintain the same specificity. They have been compared for their 
sensitivity by geometric dilutions of the sHLA-G standard reagent. In Figure 1a and 
1b the standard curves of the ELISA and Bio-Plex assays have been obtained with 
50µl of standard reagent at the concentrations of 800, 500, 400, 300 pg/ml. The 
sensitivity has been calculated with repeated measurements of a negative control and 
a 3.29 standard deviation (SD) has been calculated (Anderson DJ, 1989) (Materials 
and Methods Section). We have interpolated the data in order to obtain a standard 
curve. The low limit of detection, corresponding to the 3.29 standard deviations (SD) 
added to the mean fluorescence (FI) or optical density value of the negative control, 
reached 300 pg/ml in the Bio-Plex assay and 600 pg/ml in the ELISA system.  
We have observed a different accurateness of these two assays. As reported in Table 
3, the Bio-Plex calibration curve described the standard data with the lowest error 
(mean error: 3.2%) in comparison to ELISA calibration curve (mean error: 25.7%) 
(Plikaytis et al., 1991). The coefficient of variation (CV) for the Bio-Plex assay was 
1.7 whereas the ELISA has presented a CV of 3.1. The statistical analysis of these 
two calibration curves has documented a higher correlation in the Bio-Plex standard 
curve in comparison with ELISA (Correlation Z test: Bio-Plex p<0.0001, r2= 0.9958; 
ELISA p=0.035, r2=0.9434; Regression test Bio-Plex p=0.0001; ELISA p=0.0287). 
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The low CV, error and detection limit associated with the Bio-Plex test indicated us 
to select this assay to analyze the COC culture supernatants in order to reach lower 
sHLA-G levels with a higher degree of reliability in comparison with the ELISA 
system. The highest sensitivity of Bio-Plex assay is to be considered in comparison 
to our ELISA system and for low sHLA-G concentrations. 
3.2 Detection of sHLA-G molecules in COC culture supernatants. 
We have analyzed the COC culture supernatants by means of Bio-Plex technology.  
We have analyzed 152 COC supernatants from IVM procedures performed in 42 
women. Among the COCs, 73 matured (metaphase II stage) and 79 remained 
immature (Prophase I or Metaphase I stage). Each woman had from one to three 
mature oocytes and from one to two immature oocytes.  
We have revealed sHLA-G levels above 300 pg/ml in 14/73 (19%) COC 
supernatants that generated mature oocytes (Figure 2), in a range from 309 to 800 
pg/ml, while no sHLA-G has been detected in COC supernatants corresponding to 
immature oocytes (p= 8.4 x 10-5; Fisher exact test).  
These results have documented the presence of sHLA-G molecules only in COCs 
that produced mature oocytes. 
3.3 Western blot analysis 
We have confirmed the data obtained in COC supernatants by Bio-Plex technique 
with Western Blot analysis. In Figure 3 we have reported a representative Blot with a 
sHLA-G positive COC supernatant (second line) and a sHLA-G negative COC 
supernatant (third laine), confirming the results obtained by Bio-Plex. We have 
considered the upper bands present in all the samples as aspecific positivities and the 
37 kD positive band as HLA-G specific.  
 
3.4 sHLA-G molecules and mature COC characteristics 
The variability in sHLA-G levels could be associated to different oocyte 
characteristics. We have evaluated the morphological feature of mature COCs (Table 
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1). Taking into consideration the surrounding cumulus cell feature, we have observed 
no differences in the percentage of sHLA-G positive supernatants in Grade A mature 
COCs (expanded cumulus) (9/43; 21%) in comparison to Grade B COCs (full or 
spare cumulus): (5/30; 17%) (p=NS, Fisher exact test) (Table 4; Figure 4a). 
Considering the polar body and cytoplasmic morphological characteristics of the 
mature oocytes (Metaphase II), evaluated after cumulus removal, we have observed a 
difference in the percentage of sHLA-G positive COC supernatants which 
correspond to Grade 1 oocytes (8/22; 36%) in comparison to Grade 2 (1/15; 7%) (p= 
0.056, Fisher exact test) and Grade 3 (5/36; 14%). (p= 0.058, Fisher exact test) 
(Table 4; Figure 4b). The increased ability of COCs that generated Grade 1 oocytes 
to produce sHLA-G molecules is near the significant statistical p value, probably 
because of the low number of samples. However, the clear tendency of mature COCs 
with high score oocytes to produce more sHLA-G molecules, proposes these 
molecules as a marker of oocyte grade. Therefore it will be mandatory to increase the 
number of analyzed COCs in order to confirm this observation.  
 
3.5 sHLA-G molecules in mature COC culture supernatants subdivided into 
women 
In order to identify a possible different sHLA-G production between the mature 
COCs of the same woman, we have subdivided them between women (Figure 5a). 
The 14 supernatants with a sHLA-G positivity corresponded to 13 different women. 
Taking into consideration the women with at least one sHLA-G positive COC 
culture, we have observed different sHLA-G levels in their COC supernatant. For 
example, in Figure 5a, the woman number 1 presents two COC supernatants with no 
sHLA-G and one with 410 pg/ml of sHLA-G; woman number 10 has all the three 
COC cultures negative for sHLA-G detection.  
The women have presented different sHLA-G levels when we have compared COC 
supernatants between women. These data are of great interest because it seems that 
the COCs could be characterized by a different ability to produce HLA-G molecules.  
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Taking into consideration the previous results on oocyte morphology and differences 
in sHLA-G modulation, we have analyzed if the differences in sHLA-G levels 
between women could be correlated to different oocyte Grades. In Figure 5b we have 
reported 10 representative women. There is an association between the differences 
observed in sHLA-G levels and the oocyte Grades. The woman number 1 has two 
COC supernatant without sHLA-G classified as Grade 3 (white), and Grade 2 (grey) 
and one with 410 pg/ml of sHLA-G (Grade 1 oocyte, black); woman number 10 has 
all the three COC cultures negative for sHLA-G and Grade 3 oocytes.   
 
4. DISCUSSION      
The reduction of the number of fertilized oocytes and transferred embryos represents 
the main target of assisted reproductive medicine. During recent years, several 
studies have suggested a relationship between the production of sHLA-G molecules 
by early embryos and an increased implantation rate in IVF protocols (Fuzzi et al., 
2002; Roussev et al., 2003; Sher et al., 2004; Criscuoli et al., 2005; Noci et al., 2005; 
Sher et al. 2005a; Sher et al. 2005b; Yie et al., 2005;  Desai et al., 2006; Fisch et al., 
2007; Rebmann et al., 2007; Rizzo et al., 2007). Two studies (van Lierop et al., 2002 
Sageshima et al., 2007) have failed to detect sHLA-G molecules in embryo culture 
supernatants, probably due to technical discrepancies, as suggested by the recent 
review by Warner et al. (Warner et al., 2008). It is important to develop a very high 
quality level in sHLA-G detection methodology, to overcome these problems in 
order to evaluate the exact amount of sHLA-G produced by an in vitro cultured 
embryo (Menezo et al., 2006) and to establish the functional role of sHLA-G during 
early embryo development (Apps et al., 2008). However the data obtained by twelve 
researches suggest the production of sHLA-G as a potential marker of embryo 
implantation. Surely, it is still mandatory to evaluate embryo morphological 
parameters for an accurate embryo selection. 
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Oocytes obtained under ovarian stimulation present a variable competence and 
although molecular approaches have been proposed (Coticchio et al., 2004; Patrizio 
et al., 2007) the selection is still performed on morphological characteristics. 
Recently, the presence of sHLA-G molecules in a percentage of FFs and a significant 
association with the production of these antigens by the corresponding fertilized 
oocyte was reported (Rizzo et al., 2007). Shaikly and coauthors (Shaikly et al., 2008) 
have confirmed the presence of sHLA-G molecules in FFs but they have failed to 
identify the correlation with early embryo sHLA-G production. Several differences 
in embryo culture conditions and in the technical procedures to detect sHLA-G could 
justify the different results obtained by these two studies. The presence of sHLA-G 
in FFs is not a confirmation that it is important in oocyte maturation but it seems to 
be a marker of embryo competency. However, further studies are required to confirm 
the relationship between FFs and embryo sHLA-G production.   The goal of this 
study was to identify if sHLA-G could be also a marker of oocyte maturation. The 
oocyte maturity has been demonstrated to be important in producing good quality 
blastocysts for embryo transfer (Huang et al., 2002) and molecular markers to define 
oocyte maturity would be of great interest together with morphological 
characterization. A sHLA-G assay based on Luminex technology reaching a 
detection limit of 300 pg/ml has been proposed (Rebmann et al., 2007). We have 
developed a similar Bio-Rad’s Bio-Plex system reaching the same limit of 
sensitivity. 
Our results show that the COCs produce sHLA-G molecules during oocyte 
maturation process. The main point is that no sHLA-G molecules have been detected 
in the COC culture supernatants corresponding to immature oocytes. Some COCs 
have produced mature oocytes but no sHLA-G have been observed in their 
supernatants, underlining that sHLA-G is only one of the factor implicated in this 
process. Overall these results suggest a variable production of sHLA-G molecules in 
association with a different oocyte maturation. sHLA-G production have been related 
to the morphological characteristics of mature COCs in order to analyze the possible 
functional role of these differences. All the mature COCs have been classified 
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accordingly to their granulosa cell morphology, and to the oocyte cytoplasm and 
polar body characteristics before insemination. Taking into consideration the 
surrounding cumulus cell feature, we have observed similar percentages of sHLA-G 
positive supernatants in Grade A and Grade B mature COCs (Figure 4a). On the 
contrary, the classification using polar body and cytoplasm characteristics has 
demonstrated a tendency of Grade 1 mature oocytes to produce sHLA-G molecules 
higher than Grade 2 and Grade 3 oocytes (Figure 4b). This association could propose 
sHLA-G as a marker to identify high score mature oocytes. It will be mandatory to 
increase the number of analyzed oocytes in order to confirm our observation based 
on a statistical significance near the limit p value. The analysis of sHLA-G 
concentrations in mature COCs between women have shown different sHLA-G 
levels both in mature COCs from the same woman and in mature COCs from 
different women. These data confirm that COCs could be characterized by a different 
ability to produce sHLA-G molecules that is associated with the different oocyte 
grade. Further analyses are required to define the mechanisms that influence sHLA-
G production and the role of this antigen as directly implicated in oocyte maturation 
or as a marker of COC metabolism. A metabolic cooperation between oocyte and the 
surrounding granulosa cells is required for a complete maturation. The absence of 
sHLA-G molecules in immature COCs could suggest a role for these molecules in 
oocyte maturation. It is known that cumulus cells express innate immune related 
genes (CD14, Toll like receptors) (Liu et al., 2008) that may play critical roles in 
surveillance and cell survival during the ovulation process and HLA-G could be one 
of these mechanisms. sHLA-G could be important in the maintenance of a balance 
between pro - and anti – inflammatory effectors and the absence of this molecule in 
COC supernatants could identify a difficulty in creating the correct maturation 
microenvironment.  
In conclusion, these data demonstrate for the first time the ability of mature COCs to 
produce detectable amounts of sHLA-G molecules. This production could be a 
marker of good quality oocyte maturation and it could be used to select the best 
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oocyte to be fertilized in addition to the morphological approaches in order to reduce 
the number of produced and transferred embryos. 
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Table 1 
Details of in vitro maturation procedure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Women 
(n=42) 
Age (years) (mean ± SD) 35 ± 3 
Number of recovered oocytes per woman (mean ± SD) 7 ± 1 
Mature oocytes per woman  (%) 20 – 50 
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Table 2 
Mature COC (a) and oocyte (b) grade scoring. 
a) 
MATURE COC 
GRADE 
CUMULUS ADHESION TO OOCYTE 
GRADE A 
EXPANDED 
MULTILAYER 
FULL 
GRADE B 
FULL / SPARE 
ONE – THREE LAYERS 
SPARE 
 
 
 
b) 
MATURE OOCYTE 
GRADE 
CYTOPLASMATIC POLAR BODY 
GRADE 1 HOMOGENOUS ROUND 
GRADE 2 GRANULAR ROUND 
GRADE 3 GRANULAR FRAGMENTED/ IRREGULAR 
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Table 3 
Calculated standard concentrations fro ELISA (a) and BioPlex (b) assays 
a) 
 
Standard Conc 
(pg/ml) 
 
Calculated Conc* 
(pg/ml) 
 
%Error† 
 
 
 
800 1035 29.4 
500 535 7.0 
400 485 21.3 
300 
 
435 
 
45.0 
 
 
 
Mean error (%) 
 
25.7 
 
 
b) 
 
Standard Conc 
(pg/ml) 
 
Calculated Conc* 
(pg/ml) 
 
%Error† 
 
 
 
800 798 0.3 
500 514 2.6 
400 379 5.0 
300 315 5.0 
200 195 
3.0 
 
 
 
Mean error (%) 
 
3.2 
 
 
* For the calculated standard concentrations we used the regression curve equations. 
The r2 values were 0.9434 and 0.9958 for ELISA and BioPlex assays respectively. 
†% Error, absolute value {[(calculated concentration – standard concentration) / 
standard concentration] x100}  
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Table 4 
Subdivision of mature oocytes accordingly to COC and oocyte grading and sHLA-G 
production.  
 
 Mature oocyte 
(n=73) 
sHLA-G + 
 (n=14) 
COC Grade 
Grade A 
Grade B 
 
43 
30 
 
9 
5 
Oocyte Grade 
Grade 1 
Grade 2 
Grade 3 
 
22 
15 
36 
 
8 
1 
5 
 
 
Legends to figures 
 
Figure 1 
ELISA (a) and Bio-Plex (b) standard curves (Black line). They have been obtained 
with 50µl of standard reagent at the concentrations of 800, 500, 400, 300 pg/ml. The 
detection limit, 3.29 SD added to the mean optical density (OD) or fluorescence (FI) 
of repeated negative control (culture medium) measurements, is reported (Dotted 
line). The bold line indicates the linear regression and the dashed lines the 95% 
confidence interval. 
The r2 values were 0.9434 and 0.9958 for the ELISA and Bioplex assays respectively 
and the CV values were 3.1 and 1.7 respectively. 
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Figure 2 
sHLA-G levels in 73 COC culture supernatants that generated mature oocytes. The 
detection limit, 3.29 SD added to the mean fluorescence (FI) of repeated negative 
control (culture medium) measurements, is reported (Dotted line).  
 
Figure 3 
Western Blot analysis of COC supernatants positive (O1) or negative (O2) for 
sHLA-G detection by Bioplex system. Anti HLA-G1/HLA-G5 MEM-G1 MoAb has 
been used for the detection. HLA-G purified molecules have been used as positive 
control (+), culture medium as negative control (-).The COC supernatants have been 
loaded at the same total protein concentration that has been evaluated by Quick Start 
Bradford protein assay (Bio-Rad Laboratories, Hercules, CA, USA). The molecular 
weights (Mk) have been determined with the BenchMark (Invitrogen, CA, US) pre-
stained protein ladder (range 10-200 kD).   
 
Figure 4 
sHLA-G levels in mature COC supernatants subdivided accordingly to a) COC 
feature (Grade A and Grade B); b) characterization of oocyte polar body and 
cytoplasm (Grade 1, Grade 2 and Grade 3). The detection limit, 3.29 SD added to the 
mean fluorescence (FI) of repeated negative control (culture medium) measurements, 
is reported (Dotted line).  
 
Figure 5 
sHLA-G levels in mature COC supernatants subdivided into women (a) and in 10 
representative women with oocyte Grade (Grade 1 (black); Grade 2 (grey) and Grade 
3 (white)). The detection limit, 3.29 SD added to the mean fluorescence (FI) of 
repeated negative control (culture medium) measurements, is reported (Dotted line).  
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